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ABSTRACT 
Neoadjuvant chemotherapy (NAC) is increasingly being utilized to reduce tumor 
burden prior to surgery for breast cancer patients with stage II or higher disease. A 
pathologic complete response (pCR) to NAC has been correlated with longer 5-year 
survival and is generally considered as an absence of invasive cancer in the breast and 
axillary nodes at the time of surgery. Unfortunately, only about 10% of patients achieve 
pCR during NAC, and it may take months after the first infusion to determine response 
with methods that rely on anatomic information, such as palpation, mammography, 
ultrasound, and MRI. Functional imaging technologies such as Positron Emission 
Tomography, Magnetic Resonance Spectroscopy, and more recently, Diffuse Optical 
Spectroscopy, have shown promise for earlier predictions of therapy response. However, 
most of these techniques suffer from high expense, lack of portability, and safety issues 
related to the use of ionizing radiation or exogenous contrast agents. Furthermore, the 
repeated patient visits required by these techniques may hamper their clinical adoption 
for this purpose.  
  vii 
This project aims to develop a new wearable diffuse optical device that can be 
used to investigate if very early timepoints during a patient’s first chemotherapy infusion 
are predictive of overall response (pCR versus non-pCR) to NAC. These timepoints 
correspond to an already scheduled patient visit and have so far been unexplored for their 
prognostic value. The development of this continuous-wave diffuse optical imaging 
device was conducted in three stages. First, a prototype rigid probe was designed and 
developed to test key optical and electrical components. Second, a high optode-density 
flexible probe was design and fabricated which can conform to the curved surface of the 
human breast. Finally, a control box with miniaturized electronics and high-speed 
electronics was designed and fabricated to complete a clinic-ready system. This system 
was then tested in both the laboratory setting and as part of a normal-volunteer clinical 
study in healthy subjects during a breath hold hemodynamic challenge.  
To the best of our knowledge, this is the first imaging device that targets deep 
breast tissue measurements through a non-invasive and wearable fashion. With this 
device, real-time monitoring of fast tissue hemodynamics will enable new time-
dependent tissue optical biomarkers that have the potential to predict patients’ pathologic 
benefit from neoadjuvant chemotherapy at early timepoints. 
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CHAPTER 1. INTRODUCTION 
Locally advanced breast cancer (LABC) are breast tumors that are generally large 
(>2 cm), may have a direct extension to the skin or chest wall, or present with regional 
cancer metastasis to lymph or mammary nodes (Garg and Prakash 2015). LABC presents 
at least three substantial challenges to clinical treatment. First, the 5 year overall survival 
rate for LABC patients can be as low as 76% even after a combination of surgery, 
radiotherapy and chemotherapy (SEER Cancer Statistics Review 2018). Second, with 
traditional treatment procedures most subjects have to endure mastectomy, which 
aggressively removes the entire affected breast and axillary lymph nodes (Steligo 2017). 
Third, some primary breast tumors may not be resectable as the cancer invades the skin 
or chest wall. 
To overcome these challenges, preoperative chemotherapy, also called 
neoadjuvant chemotherapy (NAC), was introduced to shrink tumor size before surgery, 
and it has been increasingly adopted as the default treatment plan for LABC patients 
(Ragaz, Band, and Goldie 2012). The pathological outcome to NAC, proposed by the 
American Joint Committee on Cancer (AJCC) 8th edition, is staged as complete response 
(pCR): absence of invasive carcinoma in the breast and node, partial response (PR): 
downgrade in either or both tumor (T) or node (N) stage, and no response (NR): stable or 
increase in either or both T or N stage (AJCC 2017). Guided by this criteria, about 10% 
of LABC patients are expected to achieve pCR, 60% PR, and about 20 to 30% of this 
population are NR even after weeks to months of treatment, and some patients may even 
develop progressive response (Kuerer et al. 2000; Esserman 2004; Keam et al. 2013). 
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Therefore, predicting patients’ response to chemotherapy at earlier timepoints based on 
tissue anatomic or functional information could be valuable in optimizing the 
chemotherapy treatment plan and maximizing outcomes, especially for the subjects who 
fail to receive benefits from NAC.  
Several traditional clinical imaging methods have been explored for breast cancer 
monitoring during the course of NAC. For example, positron emission 
tomography/computed tomography (PET/CT) using fluorine-18-fluorodeoxyglucose 
(18F-FDG) has been reported to predict patients’ response with about 80 - 90% accuracy 
(Schelling et al. 2000; Chen et al. 2004; Biersack, Bender, and Palmedo 2008). Magnetic 
resonance imaging (MRI) and functional MRI have both demonstrated prognostic value 
in cancer monitoring (Esserman et al. 1999; Heldahl et al. 2011; Rigter et al. 2013; Dave 
et al. 2017).  Specifically, contrast-enhanced magnetic resonance imaging (CE-MRI) has 
shown superior performance in the specificity of prediction results compared to 
diffusion-weighted magnetic resonance imaging (DW-MRI), while DW-MRI has an edge 
in sensitivity (Gu et al. 2017). Ultrasonography and mammography have both been 
applied for NAC monitoring as well, but their prognostic accuracy is not comparable to 
the imaging modalities mentioned above (Tadayyon et al. 2016; Gu et al. 2017; Nam et 
al. 2017). 
Unfortunately, these clinical imaging modalities are accompanied by high 
expense, lack of portability, and safety issues due to the use of ionizing radiation or 
exogenous contrast agents. In contrast, diffuse optical imaging, which utilizes near 
infrared light and portable imaging platforms, avoids these limitations. NAC monitoring 
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with diffuse optical imaging thus can be far more adaptive to patients’ scheduled 
chemotherapy infusions. Among the variants of diffuse optical imaging, both continuous-
wave (CW) and temporally-modulated (i.e. frequency-domain (FD)) are popular in 
academic research exploring chemotherapy response. For example, researchers at 
Dartmouth College developed a FD diffuse optical imaging system that employs radio-
frequency intensity modulated near-infrared (NIR) light to quantitatively image both the 
scattering and absorption coefficients of tissue (Pogue et al. 1997). The Beckman Laser 
Institute at University of California, Irvine and the University of Pennsylvania both  
developed hybrid FD/CW clinical prototypes for breast imaging (Shah et al. 2001a; 
Culver et al. 2003). Commercial systems for diffuse optical breast imaging have also 
been developed and approved (Intes et al. 2004). Previous studies with these instruments 
have demonstrate that the pathological response of LABC patients to neoadjuvant 
chemotherapy can often be determined within weeks to months after the start of 
treatment, and are typically associated with a decrease of hemoglobin concentration and 
water content, and an increase of lipid concentration (Cerussi et al. 2007; Jiang et al. 
2009; Choe and Durduran 2012).  
Most recently, the acute response (first hours to days of treatment) to NAC has 
also been shown to manifest through significant difference between responders and non-
responders when monitored with diffuse optical instruments. For example, in a study of 
23 LABC subjects, tissue oxyhemoglobin concentration was determined to discriminate 
the pathological outcome from chemotherapy on the very first day after initial infusion 
(Roblyer et al. 2011). This study, if further confirmed with a larger sample size, may 
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indicate that a patient’s response to chemotherapy can be confirmed within hours of the 
start of treatment, which could substantially minimize treatment burden and ineffective 
chemotherapy. 
This work aimed to address several unmet needs of existing breast cancer diffuse 
optical monitoring devices. First, previous designs typically deliver light to and from the 
patient using optical fibers. This type of design is often bulky, heavy, and fragile. Second, 
the optical probe or patient/device interface is typically rigid and poorly conforms to the 
natural shape of human tissue. This is limiting as it may be uncomfortable for the patient, 
especially during extended measurements. Typical solutions include adjusting the 
position of individual fiber tips (Flexman et al. 2011) or adjusting the distance or the 
angle between compressing plates (Ge et al. 2008; Choe et al. 2009; Anderson et al. 
2015). Third, for optical probes with limited number of light sources and detectors, a 2D 
mapping of tissue properties may require the probe head to be sequentially scanned over 
gridded positions on the skin (Roblyer et al. 2011). Therefore, data acquisition for each 
iteration may take 10s of minutes, and poor temporal and spatial resolution from this 
imaging protocol excludes the possibility of real time monitoring of tissue 
hemodynamics. 
This thesis describes three iterations of breast tissue imaging systems that 
progressively address the limitations described above. The overall goal of this work was 
to develop a wearable probe that could perform breast cancer therapy monitoring at high 
spatial and temporal resolution. The final product of this work is a clinical-ready high-
optode density and flexible wearable probe and electronics control box. This imaging 
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probe has been validated through both in vitro and in vivo studies.  
This thesis is organized into five chapters and one appendix. Chapter 2 describes 
the background and motivation of this work, including breast cancer and treatment, 
diffuse optics theory and its applications for breast tissue imaging, and CW diffuse 
optical spectroscopic imaging system instrumentation. It also includes a description of the 
preliminary system designs that led to the development of the wearable tissue imaging 
device. Chapter 3 through 4 describe the system design, characterization, and verification 
and validation of two iterations of the wearable imaging device. Chapter 5 is a summary 
of this work and future directions. The Appendix section includes the electronic and 
mechanical computer-aided design (CAD) of the imaging systems and the recipes for 
tissue simulating optical phantoms used in this work. 
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CHAPTER 2. BACKGROUND 
2.1. Introduction 
The relevant background for this work includes the fundamentals of breast cancer 
treatment, diffuse optical spectroscopic imaging, algorithms for solving diffuse optical 
inversion problems, and the electrical engineering theory relevant to diffuse optical 
imaging system design.  
2.2. Breast cancer treatment 
The earliest recorded case of breast cancer comes from the 1600 BC Edwin Smith 
Papyrus in ancient Egypt (American Cancer Society 2018). For thousands of years, 
people have suggested a variety of causes to account for the development of breast 
cancer. The ancient Greeks described breast cancer as a humoral disease, and this belief 
lasted until the 17th century. By then physicians challenged the humoral theory of cancer, 
and attributed the cause of breast cancer to patients’ living style. By the 19th century, the 
hopelessness of not knowing gave rise to a wave of psychological theories, which argued 
the origin of breast cancer is due to cancerophobia (Brechon 2012). Rigorous 
investigations into the origins and development of breast cancer were facilitated with the 
advance of modern medicine, which gave birth to more systemic theories of breast 
cancer. This included the realization that breast cancer often originates from specific 
genetic mutations including (but not limited to) mutations in the BRCA1 and BRCA2 
genes (Hall et al. 1990; Wooster et al. 1995), the p53 gene (Malkin et al. 1990), the 
PTEN gene (Li et al. 1997), and the PIK3CA gene (Campbell et al. 2004). 
In one sense, cancer can be thought of as a genetic disease, and mutations in key 
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genes promote abnormal cell growth and proliferation from the milk ducts or the lobules 
of the female breast. This leads to Intraductal Carcinoma or Lobular Carcinoma. The 
former accounts for 85% of breast cancer cases (Welsh 2013). Though less prevalent, 
several other types of breast cancer may appear as Tubular Carcinoma, Mucinous 
Carcinoma, and Papillary Carcinoma. The stage of breast cancer is typically described 
according to the TNM system, and are ranked from stage 0 (carcinoma in situ) to 4 
(metastatic breast cancer). The TNM stages for LABC are 2 or higher. Breast cancer is 
widespread across the globe. According to the cancer statistics from National Cancer 
Institute, in the U.S., about 1 in 8 women will develop invasive breast cancer over the 
course of her lifetime (National Cancer Institute 2018). In 2018, breast cancer is 
estimated to include 15.3% of new cancer cases, and contributes to 6.7% of all cancer 
deaths (National Cancer Institute 2018). 
Clinical treatment of breast cancer largely falls within two categories. Local 
treatments aim to remove the malignant lesions within the breast and the affected lymph 
nodes. Examples include surgery and radiation therapy. Systemic treatments, including 
chemotherapy, hormone therapy, and targeted therapy, are administered with the goal of 
eliminating cancer cells throughout the body. Due to the complexity of breast cancer, a 
treatment plan is tailored to the biology of the tumor, the cancer stage, and the physical 
condition of the subject whenever possible. Most patients, however, will experience a 
combination of surgery, local therapy, and systemic therapy. 
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2.3. Breast tissue composition as measured with diffuse optical technologies. 
Diffuse optical technologies utilize near-infrared light to extract concentrations of 
chromophores, or light absorbing species in tissue. This typically includes oxy and 
deoxyhemoglobin, water, and lipids (Jacques 2013). Prior studies have measured the 
composition of healthy and cancerous breast tissue using diffuse optical technologies, and 
a summary of these results are included here.  
The composition of human breast tissue is strongly correlated with the 
menopausal status of a female subject (Cerussi et al. 2001; Shah et al. 2004). On average, 
the lipid content increases from approximately 30% to 68%, while water content 
decreases from 45% to 10% before and after menopause (Cerussi et al. 2001). 
Hemoglobin has been shown to decrease from more than 40 𝜇𝑀 to less than 15 𝜇𝑀 due 
to absence of the menstrual cycle (Cerussi et al. 2001). A summary of the results of 
several relevant studies that measured total hemoglobin (THb) and oxygen saturation 
(StO2) are shown in Table 2.1. 
Study 
Sample 
size 
Menopausal status THb (𝝁𝑴) StO2 (%) 
(Cerussi et al. 2001) 15 Pre 40.5 76.3 
(Shah et al. 2004) 18 Pre 26.5 74 
(Cerussi et al. 2001) 6 Post 14.6 91.9 
(Shah et al. 2004) 13 Post 15.1 75 
(Durduran et al. 2002) 52 N/A1 34 68 
Table 2. 1 Hemoglobin composition in healthy female breast tissue 
  
1: The age distribution of subjects is 32±12 years, which indicate the majority are premenopausal. 
For details, see Figure 5 of the reference. 
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The dynamic changes of THb and StO2 with respect to time and space are the 
focus of this study. Changes in THb may be potentially linked to vessel dilation or 
contraction caused by partial pressure variations of carbon dioxide in the blood, or an 
imbalance of flow rate between oxygenated and deoxygenated blood (Cipolla 2009). StO2 
is calculated as the percentage of oxygenated hemoglobin (HbO2) concentration to THb 
concentration, which serves as an indirect biomarker of tissue metabolic rate. 
2.4. Breast tissue optical properties 
Biological tissue, if examined from the perspective of light-tissue interactions, is 
well described by its optical absorption 𝜇𝑎 and optical scattering 𝜇𝑠  coefficients, which 
indicate the average distance that a photon is likely to propagate before undergoing either 
an absorption or scattering event. Tissue absorption occurs as the incoming photons 
transfer optical energy to electrons, which pump them up into higher energy states; while 
the scattering events are the result of gradients and discontinuities in the index of 
refraction at the spatial scale from nanometers to micrometers. At NIR wavelengths, 
tissue scattering is typically one or two orders greater than absorption strength, and 
biological tissue is typically described as an optically diffuse media (Jacques 2013). 
2.4.1 Breast tissue absorption 
Figure 2.1 shows the weighted absorption contribution from the major absorbers 
in pre-menopause breast tissue at wavelengths between 600 nm to 900 nm. This plot was 
produced based on the breast composition properties described in section 2.3. The 
concentration of oxyhemoglobin (HbO2) is 19.6 𝜇𝑀, the concentration of 
deoxyhemoglobin (HHb) is 6.9 𝜇𝑀, and the tissue is assumed to contain 34.5% water, 
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and 41% fat. The extinction coefficient spectrum of water is adapted from (Hale and 
Querry 1973), while the extinction coefficient spectrum of hemoglobin is adapted from 
omlc.org/ (Prahl 1998). Hemoglobin dominates the absorption of breast tissue for the 
majority of the spectrum. 
 
Figure 2. 1 Premenopausal breast tissue optical absorption in near infrared. 
The chromophore composition of breast tissue and the tissue optical absorption 
are linked through Beer’s Law, which describes the absorption coefficient 𝜇𝑎(𝜆) as the 
sum of individual absorbers’ contribution, 
𝜇𝑎(𝜆) = 2.303 ∙∑𝜀𝑖
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where 𝜀 and 𝐶 are is the molar extinction coefficient and the concentration of a tissue 
chromophore, respectively.  
2.4.2 Breast tissue scattering 
The scattering of photons by biological tissue at NIR wavelengths are 
predominantly described by Mie scattering due to the fact that the size of organelles, 
membranes and other intracellular structures generally are less than one order difference 
from the illumination wavelength (Bigio and Fantini 2016). The structural components of 
the extracellular matrix, including collagen and elastin, generally scatter incident photons 
according to Rayleigh scattering. The polar plot in Figure 2.2 represents the probability 
of photon distribution from Mie scattering events, with unpolarized light and a one-
micron isotropic scattering particle. The scattered electromagnetic field is highly 
anisotropic. It indicates a photon is more likely to be forward scattered than back 
scattered, with the peak probability along the incident direction. This field distribution 
can be quantitatively summarized by an anisotropy factor 𝑔,  
𝑔 ≡ 〈𝑐𝑜𝑠𝜃〉 = ∫ 𝑐𝑜𝑠𝜃 ∙ 𝑝(𝜃)𝑑Ω
4𝜋
 
where 𝜃 is the polar angle between the incident and scattered photon, 𝑝 is the scattering 
phase function, Ω is the solid angle of the scattered photon. For most biological tissue, 𝑔 
is typically around 0.9 (Jacques 2013). By introducing 𝑔 factor, the scattering mean free 
path 1/𝜇𝑠 can be extended to 1/((1 − 𝑔)𝜇𝑠), which represents the mean distance after 
which a photon’s direction becomes random. The term (1 − 𝑔)𝜇𝑠 can be expressed as 𝜇𝑠
′ , 
which is called the reduced scattering coefficient.  
(2) 
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Figure 2. 2 Normalized electromagnetic field distribution of Mie scattering to the 
incident light at 750 nm by a one-micron spherical particle. The refractive index of 
sphere is 1.5, while the refractive index of medium is 1.33. Data adapted from online 
calculation tool: https://omlc.org/calc/mie_calc.html 
2.4.3 The Modified Beer-Lambert law 
A simple equation for calculating tissue functional and the optical properties from 
diffuse optical measurement is the modified Beer-Lambert law (MBLL). In 1988, Delpy 
and his colleagues developed this concept, and validated it through Monte Carlo 
simulation and experimental time-domain diffuse optical imaging (Delpy et al. 1988). A 
central idea of this method is to account for the fact that both absorption and scattering 
contribute to photon pathlength. It accounts for this by multiplying the optical density 
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term with a differential pathlength factor (𝐷𝑃𝐹). The 𝐷𝑃𝐹 can be expressed as a function 
of tissue optical properties and light emitter and detector separation 𝑑 (Scholkmann and 
Wolf 2013):  
𝐷𝑃𝐹(𝜆) =
1
2
(
3𝜇𝑠
′(𝜆)
𝜇𝑎(𝜆)
)
1/2
[1 −
1
(1+𝑑∙(3𝜇𝑠
′(𝜆)∙𝜇𝑎(𝜆))1/2
] 
This expression indicates that DPF increases with greater 𝜇𝑠
′ , and decreases with greater 
𝜇𝑎. The MBLL can be written as: 
𝐼(𝜆) = 𝐼0(𝜆)𝑒
−𝜇𝑎(𝜆)∙𝑑∙𝐷𝑃𝐹(𝜆)+𝐺(𝜆) 
where 𝐺(𝜆) is a wavelength, medium, and geometry dependent constant. 𝐼0 and 𝐼 are 
optical intensity measured at light emitter and detector, respectively. For repeated tissue 
measurements with an unchanging imaging setup, the 𝐺(𝜆) factor can be cancelled out 
between successive measurements, thus leading to the differential format of MBLL for 
the (𝑘 + 1)𝑡ℎ measurement, which is expressed in terms of the change in tissue optical 
density (OD):  
∆𝑂𝐷 = − log (
𝐼(𝑡 = 𝑘 + 1, 𝜆)
𝐼(𝑡 = 𝑘, 𝜆)
) =∑Δ𝜇𝑎
𝑖,𝑘(𝜆) ∙ 𝐷𝑃𝐹(𝜆)
𝑁
𝑖=1
∙ 𝑑 
The differential MBLL provides a convenient way to compute the changes in 
tissue absorption using repeated optical physiological monitoring, but it is a simplified 
method that carries assumptions that may be unrealistic in certain circumstances. First, it 
assumes tissue scattering changes are small compared to changes in absorption. This 
condition is likely to be well satisfied only during short timeframe tissue hemodynamic 
monitoring. Second, it assumes that the underlying tissue is optically homogeneous, and 
changes within the tissue are homogeneous from one measurement to the next. Therefore, 
(3) 
(4) 
(5) 
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when utilizing the differential MBLL as a tool for extracting tissue parameters, one 
should be aware of these assumptions and how they may affect accuracy.  
2.5. Light propagation in diffusive media 
2.5.1 Transport theory 
Photon transport in biological tissue can be described by the Radiative Transfer 
Equation (RTE) based on conservation of energy within infinitesimal volume 𝑑𝑉(𝒓), 
where 𝒓 is a vector pointing from light source to a spatial point of interest. It describes 
radiance 𝐿(𝒓, Ω̂, 𝑡), defined as the optical power received per unit area, per unit solid 
angle that is propagating along direction Ω̂(𝜃, 𝜑) at time 𝑡 from differential volume 𝑑𝑉. 
RTE considers changes in radiance due to photon diffusion, photon collision and light 
sources.  
1
𝑐
𝜕𝐿(𝒓,Ω̂,𝑡)
𝜕𝑡
= −Ω̂ ∙ ∇𝐿(𝒓, Ω̂, 𝑡) − (𝜇𝑎 + 𝜇𝑠)𝐿(𝒓, Ω̂, 𝑡) + 𝜇𝑠 ∫ 𝐿(𝒓, Ω̂, 𝑡)𝑝(Ω′̂, Ω̂)𝑑Ω
′
4𝜋
+
𝑞(𝒓, Ω̂, 𝑡) 
where 𝑞(𝒓, Ω̂, 𝑡) is light source. The positive terms on the right-hand side of Equation 6 
indicates photon accumulation within 𝑑𝑉 through incoming photon scattering and 
generation, while the negative terms indicates photon dissipation through outgoing 
scattering and absorption. The difference between these two processes represent the net 
changes in photon density. 
The transport theory is a rigorous and universally applicable method in describing 
photon movements in diffusive media, but it does not provide a convenient analytical 
(6) 
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expression of radiance, and numerical computation with RTE is generally accessible 
through Monte Carlo methods (Wang, Jacques, and Zheng 1995). 
2.5.2 Diffusion equation 
The diffusion equation is the truncated result after the radiance, the source term, 
and the scattering phase function of the RTE are expanded into a set of basis functions. In 
the time domain it can be written as 
1
𝑐
𝜕Φ(𝒓, 𝑡)
𝜕𝑡
+ 𝜇𝑎Φ(𝒓, 𝑡) − ∇[𝐷∇Φ(𝒓, 𝑡)] = 𝑞(𝒓, 𝑡) 
where D = 𝑐𝑛/[3(𝜇𝑠
′ + 𝜇𝑎)] is diffusion coefficient and  𝑐𝑛 is the speed of light in 
diffusive media. Φ(𝒓, 𝑡) is the fluence rate, which represents the incoming photons per 
unit area, per unit time from all solid angles. 
There are three assumptions required to simplify the RTE into the diffusion 
equation. First, the reduced scattering coefficient 𝜇𝑠
′  is much larger than 𝜇𝑎; second, the 
source emission is isotropic; third, the time for substantial current density change is much 
longer than the time to traverse one transport mean free path. A detailed derivation of the  
diffusion equation from RTE can be found in Sections 9.2 to 9.5 in the textbook 
Quantitative Biomedical Optics (Bigio and Fantini 2016). The optical properties of 
biological tissue at NIR wavelengths can typically satisfy these assumptions after a 
propagation distance greater than several transport mean free paths (Yoo, Liu, and Alfano 
1990). Therefore, the diffusion equation can be used as an important component in 
methods for analyzing diffuse optical imaging measurements. It should be noted that the 
observation of fluence rate is measured in the “far field”, which is typically centimeters 
away from the light source. 
(7) 
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2.5.3 Analytical solution of diffusion equation for CW diffuse optical imaging 
Given a homogeneous distribution of tissue optical properties measured with a 
CW light source, the diffusion coefficient in Equation 7 becomes spatially homogeneous, 
and the fluence rate is time-independent, further simplifying the diffusion equation: 
𝜇𝑎Φ(𝒓) − 𝐷∇
2Φ(𝒓) = 𝑞(𝒓) 
For a semi-infinite geometry and Robin boundary condition at the air-tissue interface; the 
fluence rate evaluated at a point 𝐴 in tissue can be written as (Bigio and Fantini 2016):  
Φ𝑆→𝐴 = −
3(𝜇𝑠
′ + 𝜇𝑎)
4𝜋
2𝑧0𝑧 (𝜇𝑒𝑓𝑓 +
1
𝒓
)
𝑒−𝜇𝑒𝑓𝑓|𝒓|
|𝒓|
 
where |𝒓| is the distance between physical source location 𝑆 and point 𝐴, 𝑧0 is the 
location of the effective source depth from tissue-air interface. 𝜇𝑒𝑓𝑓 = √3𝜇𝑎(𝜇𝑠′ + 𝜇𝑎) is 
the effective attenuation coefficient. Figure 2.3 (a) shows the fluence rate distribution 
based on Equation (9), as an incident pencil beam transmits into diffusive media, photon 
propagation gets randomized, which turns the fluence rate distribution into an isotropic 
profile along the depth of the photon penetration. 
 
 
(8) 
(9) 
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Figure 2. 3 (a) Fluence rate distribution in semi-infinite homogeneous diffusive 
media (𝝁𝒂 = 0.01/mm, 𝝁𝒔
′ = 1/mm) generated by incident pencil beam. (b) 
Sensitivity function of optical signal at detector position 𝑫, with a source-detector 
separation of 30 mm. 
For non-invasive deep tissue imaging, one is typically not only interested in the 
measured fluence rate at the surface, but also the propagation path of the detected 
photons. The probability for a photon reaching photodetector 𝐷 via the aforementioned 
point 𝐴 is proportional to the sensitivity of detected signal to local optical property 
perturbation at point 𝐴. The sensitivity function thus correlates the actual CW optical 
signal with optical property changes in diffusive media, which can be constructed by 
multiplying fluence rate from source 𝑆 to point 𝐴, then to photodetector 𝐷. This can be 
written as (Bigio and Fantini 2016):  
𝑠(𝒓) =
Φ𝑆→𝐷(𝝁𝒓 + 𝛿𝝁𝒓=𝐴) − Φ𝑆→𝐷(𝝁𝒓)
𝛿𝝁𝒓=𝐴
= 𝑘 ∙ Φ𝑆→𝐴 ∙ Φ𝐴→𝐷 (10) 
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where 𝑘 is a spatially independent factor of fluence rate. Figure 2.3 (b) indicates the 
propagation path of the detected photons traverse a banana-shaped volume in the 
underlying homogeneous diffusive media. As a rule-of-thumb, the depth of penetration, 
defined as the FWHM of sensitivity in the plane perpendicular to light source and 
detector, is generally about or less than half of the source-detector separation. This 
potentially allows diffuse optical imaging to detect the primary tumors in breast tissue, as 
well as metastatic lesions embedded up to several centimeters deep in tissue. 
2.5.4 Numerical solutions to the diffusion equation 
The analytical forms of the fluence rate and sensitivity function assume 
homogeneous tissue optical properties. For inhomogeneous diffusive media, which is a 
closer estimate to human breast tissue, numerical tools are required for fluence rate 
calculations. Relevant methods include the Finite Difference Method, the Finite Volume 
Method, and Finite Element Method (FEM). FEM is considered as the most popular 
option due to its ability to account for conservative systems (e.g. heat conduction, fluid 
dynamics) and non-conservative systems (e.g. light-tissue interactions), and the ability to 
create adaptive meshes for irregular boundaries. FEM requires the imaging domain to be 
divided into interconnected elements, where the differential forms of diffusion equation 
are discretized and evaluated over mesh nodes. 
Consider an optical probe with 𝑀 source-detector pairs, and a FEM mesh with 𝑁 
nodes inside. If only optical absorption changes are considered, the discretized expression 
of sensitivity function for a CW measurement, also called the Jacobian matrix, can be 
written in terms of a 𝑀 ×𝑁 matrix: 
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The Jacobian matrix can be computed using FEM methods for arbitrary 
measurement geometries and tissue optical property spatial distributions.  
2.6. Diffuse optical tomography 
Tomographic reconstruction of tissue optical or functional properties may be 
considered as the opposite or inverse of the process used to calculate optical fluence rates 
described in Section 2.5. Searching for the optimal reconstructed tissue properties is 
mathematically equivalent to solving a least square problem, where the calculated fluence 
rate Φ𝐶 is the best approximation of the measured data Φ𝑀. This can be expressed as:  
𝝁 = 𝑎𝑟𝑔𝑚𝑖𝑛{‖Φ𝑀 − Φ𝐶‖
2} 
2.6.1 Levenberg-Marquardt (LM) minimization 
Without spatial prior estimates of tissue optical properties, minimization to the 
object function in Equation 11 can be achieved through the LM algorithm, which 
iteratively reduces the cost function. To reach a local minimal within the solution space, 
the first order derivative of object function is set zero, which leads to the update equation 
for the 𝑖th iteration of minimization: 
[𝐽𝑇𝐽 + 𝜆 ∙ 𝒅𝒊𝒂𝒈(𝐽𝑇𝐽)]Δ𝝁𝑖 = 𝐽
𝑇𝛿𝑖−1 
(11) 
(12) 
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where 𝜆 is a regularization parameter that monotonically decrease with each iteration. 
Since the square matrix 𝐽𝑇𝐽 is ill-conditioned, Kenneth Levenberg and Donald Marquardt 
added and modified a diagonal matrix term respectively, so as to stabilize and optimize 
solution searching (Levenberg 1944; Marquardt 1963).  
The inverse problem described above is ill-posed due to the vast number of 
unknown tissue optical properties (10K~10M nodes for 3D mesh) that need to be 
determined by at most hundreds of independent measured variables. A minimized object 
function is typically not enough to reach accurate reconstruction results that represents 
the actual tissue optical or functional properties, and the reconstructed tomographic 
results and rate of convergence are largely dependent on the initial guess of tissue 
properties (Madsen, Nielsen, and Tingleff 2004). 
2.6.2 Tikhonov regularization minimization 
To overcome the concerns raised in Section 2.6.1, in many cases, tissue spatial 
priori information are considered and utilized in the object function:  
𝝁 = 𝑎𝑟𝑔𝑚𝑖𝑛 {‖Φ𝑀 − Φ𝐶(𝝁, 𝒓𝒅)‖
2 + 𝜆 ∙ ‖𝑳(𝝁 − 𝝁𝑝𝑟𝑖𝑜𝑟)‖
2
} 
where 𝑳 is a regularization matrix and 𝜆 serves as a regularization parameter that stays 
constant with each iteration. Figure 2.4 shows the iterative solution searching process in a 
2D solution space. The value of object function is not only constrained by the sum of 
squared fluence rate residuals, which is represented by the isolines, but also limited by 
tissue optical property residuals, which is represented by the size of the shaded circle.  
(13) 
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Figure 2. 4 Iterative solution searching constrained by fluence rate difference also 
regularization term. Adapted from Wikipedia 
2.7. CW diffuse optical spectroscopic imaging instrumentation 
CW diffuse optical spectroscopic imaging (DOSI) is the simplest and most 
economic form of diffuse optical imaging. As shown in Figure 2.5, the optical signals for 
CW measurements are generally DC signal or modulated at a low (i.e., KHz) modulation 
frequency.  
 
Figure 2. 5 Format of optical signals in a CW measurement 
The simplicity of this technique promotes its wide applications in the domain of 
consumer devices, such as fitness trackers, as well as in medical devices including pulse 
oximeters. Applications of CW diffuse optical tissue imaging typically assumes that the 
  
22 
tissue scattering properties are constant over seconds to minutes timescales, due to the 
generally stable distribution of intercellular and extracellular particle density. For the past 
several decades, CW DOSI has emerged as a new technology for breast cancer 
monitoring. This section will review the components of CW DOSI instruments and then 
describe several representative instrument designs that have been utilized in prior clinical 
studies. 
2.7.1 Light sources 
White light sources, such as halogen lamps, are commonly used for CW DOSI 
because of the importance of using multiple wavelength to extract chromophore 
concentrations (Bevilacqua et al. 2000; Cerussi et al. 2006). The spectrum of halogen 
lamps, coming from the black-body radiation of hot tungsten filament, generally extends 
from the ultraviolet (UV), visible, near-infrared, and infrared wavelengths. Light emitted 
from white light sources are typically collected and delivered through optical fibers, 
while the optical spectrum for CW imaging can be continuous or selectively filtered into 
discrete wavelengths. 
Light emitting diodes (LED) are also popular light source for CW DOSI 
instruments (Bozkurt et al. 2005; Zhang, Yan, and Strangman 2011; Eggebrecht et al. 
2014; Yuan et al. 2014; Teng et al. 2017). LED emission spectra are largely determined 
by the bandgap between the conduction and valence bands of the semiconductor 
substrate. For LEDs with peak emission at NIR wavelengths, the substrate of PN junction 
is typically Aluminum Gallium Arsenide, Gallium Arsenide, or Gallium Arsenide 
Phosphide (Dakin and Brown 2006). 
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Applications of LEDs for tissue measurement have both pros and cons. On the 
negative side: 
1. LED light sources are generally not friendly for fiber coupling due to their 
Lambertian emission profiles. 
2. For tissue contact measurement, LED light source poorly approximate a pencil 
beam, which is often an assumption in the simulation of diffuse optical imaging 
(Farrell, Patterson, and Wilson 1992).  
3. Due to temperature sensitivity of the underlying semiconductor substrate, the 
central wavelength of LEDs is subject to change due to package overheating 
(Dakin and Brown 2006).  
However, on the positive side:  
1. Compared to white light sources, LEDs are relatively efficient in energy 
conversion from electricity to light. 
2. The smallest standardized LED size can be on the order of tens of microns, which 
can be fit into miniaturized consumer and clinical wearable formats. 
3. Some LED packages support total internal reflection lenses, which substantially 
decrease the half angle of light emission from around 50 degrees to less than 15, 
which turns the incident light from LEDs into a closer estimate to pencil beam. 
Laser diodes are also widely used in CW diffuse optical imaging designs 
(Tamura, Hoshi, and Okada 1997; Macnab and Stothers 2008; Flexman et al. 2011). 
Compared to the previous two classes of light sources, the emitted light from laser diodes 
is coherent, with much smaller divergence angles, and the spectral width is typically at 
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the level of one tenth of nanometer (Daly 1984). The default approach for light delivery 
from laser diodes is through optical fibers, which complicates their potential use in 
wearable optical devices for the human body. 
Among these three light source options, the LEDs were used for the wearable 
probe presented in this work, due to their inherent and unparalleled advantage in package 
size for tissue contact measurement. 
2.7.2 Light detectors 
The most common photodetectors used in CW DOSI instrumentation are 
photomultiplier tubes (PMT), photodiodes (PD) and avalanche photodiodes (APD). 
PMTs are a type of highly sensitive photo-detection devices that accelerate 
photoelectrons through an electric field, and amplify the photocurrent through a series of 
cascaded dynodes. Though PMTs have a gain between 103 to 106, their dynamic range is 
limited to approximately 30 dB. This makes PMT an ideal photodetector for low light 
detection, but less desirable for optical detection of tissue hemodynamics as changes in 
hemoglobin concentration may strongly alter light attenuation during a measurement. 
Also, the bulky size of PMT sensing module and its high voltage power supply are not 
feasible for wearable physiological sensing. 
PDs operate by absorption of photons or charged particles and generate a flow of 
current in an external circuit proportional to the incident power. As a type of basic 
structure for PDs, the P-N junction is formed by diffusing either a P-type impurity, such 
as Boron, into an N-type bulk silicon wafer, or an N-type impurity, such as Phosphorous, 
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into a P-type bulk silicon wafer. Figure 2.6 shows the schematics of a planar diffused 
silicon photodiode.  
 
Figure 2. 6 Schematics of a planar diffused silicon photodiode. Adapted from 
technical notes from OSI Optoelectronics. 
There are several key aspects of PDs to consider in optical sensor design. First, 
the spectral sensitivity of the substrate. Silicon is typically chosen as the substrate of PDs 
for NIR light detection due to its spectral sensitivity from approximately 300 to 1100 nm. 
Second, the responsivity of a PD is a measure of the photocurrent generated per unit 
detected optical power, which is a function of quantum efficiency, incident wavelength, 
and the detector gain. Therefore, it is desirable if the PD exhibits high responsivity to the 
wavelengths of light source. Third, noise-equivalent power (NEP), defined as the 
minimum input optical power that generate a photocurrent equal to the noise current in a 
1 Hertz bandwidth. This determines, in part, the sensitivity of PD to low light detection. 
Fourth, the impedance of PD. This can be affected by the dimension, package, and 
operating mode of the PD. This frequency-dependent parameter determines the rise and 
fall time of the device, which limits the frequency of light it can measure. Fifth, noise. A 
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PD may suffer from statistical fluctuation in both the photocurrent and the dark current, 
which contributes to shot noise. This is the dominate noise source when a PD is biased 
with an external voltage (Kingston 1995). Another noise source is due to the thermal 
generation of carriers, which is thus named as thermal noise. Sixth, operating mode. A 
PD can be operated in photoconductive mode or photovoltaic mode, depending on the 
implement of a bias voltage. For light collection in tissue measurement, photoconductive 
mode is much more common due to shorter temporal response and better linearity, 
although stronger dark current and noise current can be expected. 
An APD is a high-speed, highly-sensitive photodiode with an internal gain on the 
order of 100. The electron-hole pairs are generated from exposure to light with higher 
photon energy than the band gap energy. A reverse voltage applied to the PN junction of 
the APD causes the electrons to drift towards N layer and holes towards P layer. An 
avalanche effect occurs when the electron-hole pairs acquire sufficient energy to create 
additional electron pairs by colliding with the crystal lattice. However, compared to a PD, 
an APD typically picks up more noise, needs a high voltage supply, and its dynamic 
range is lower than most PDs. 
Among these three light detector options, the PDs were used for the wearable 
probe presented in this work, due to their inherent advantage in package size for tissue 
contact measurement, as well as the unparalleled dynamic range needed from the optical 
measurements at different source-detector separations. 
2.7.3 Electronic switches and multiplexers 
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A CW DOSI imaging system, especially with multiple optodes, requires 
electronic switches and multiplexers. Electrical switches are a type of devices controlling 
the on and off of signal line. As an example, a metal-oxide-semiconductor field-effect 
transistor (MOSFET) is a three-terminal device that can be for electrical current 
switching applications. For example, it can be used to control the forward current to an 
LED during CW measurements.  
Multiplexer (MUX) integrated circuits (ICs) are devices that select and route one 
of several analog or digital input signals into a single line. In terms of multi-optode CW 
DOSI instrumentation, MUX can be implemented to collect from multiple optical sensing 
channels. Demultiplexers (DEMUX), on the other hand, reverses the channel switching 
process in MUXs, and can be applied to switch driving current into different light 
sources.  
Multiplexers in CW diffuse optical measurement can be implemented to perform 
frequency-division multiplexing (FDM) (Flexman et al. 2008) and time-division 
multiplexing (TDM) (Teng et al. 2017). FDM is inherently an analog technology, where 
continuous data acquisition is performed by combining electrical sensing signals at 
different modulation frequencies. TDM is a digital technology which uses time to 
separate the different data streams. TDM sequentially scans individual input channels 
then deliver signals to associated receivers.   
With the help of digital bus and serial communication protocols, the multiplexing 
of large numbers of measurement channels can be engineered with elegance. For 
example, the serial control protocol I2C allows a master I2C processor to control up to 
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127 slave processors through only a data line (SDA) and a clock line (SCL). Channel 
selection within each slave can be chosen by calling its 8-bit register address. This 
protocol, due to its simplicity in wire connection and large capacity in channel selection, 
is widely applied in portable consumer and medical tissue imaging devices, and is used in 
the wearable probe developed in this work. 
2.7.4 Previous CW DOSI instrumentation designed for breast imaging 
Several prior CW instruments helped to inspire the work conducted in this thesis. 
For example, in 2010, researchers at Tufts University developed a broadband continuous-
wave optical mammography system (Yu et al. 2010) which is shown in Figure 2.7. 
Imaging on the breast is performed in a parallel plate geometry where the breast is mildly 
compressed between two polycarbonate plates.  
 
Figure 2. 7 Instrument diagram of a broadband optical imaging system. Adapted 
from (Anderson et al. 2015). 
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This instrument is capable of extracting the concentrations of tissue hemoglobin, water, 
and lipids, as well as the oxygen saturation in two-dimensional optical mammograms 
(Anderson et al. 2015). 
A different tomographic breast tissue imaging system was developed at Columbia 
University and utilizes modulated light sources (~KHz) and aligns optical fibers into a 
hemisphere geometry that fits to the shape of female breast tissue. 
 
Figure 2. 8 Instrument diagram of a CW tomographic imaging system. Adapted 
from (Flexman et al. 2011). 
This system performs real-time monitoring of breast tissue hemodynamics as a 
subject performs a breathhold. Clinical results derived from this instrument demonstrate 
the potential of breast hold measurement for separating healthy subjects from breast 
cancer subjects (Flexman et al. 2013). 
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Figure 2. 9 System diagram and optical probe layout of a CW/FD diffuse optical 
imaging system design. Adapted from (Cerussi et al. 2006) 
Our research group use a CW/FD DOSI system designed by the Beckman Laser 
Institute at University of California, Irvine. The CW module in this instrument is 
complementary to the FD measurements, and ultimately allows quantitative tissue optical 
property extraction over a continuous NIR spectrum. Figure 2.9 shows the system 
schematic diagram, also the layout of the optical probe for both CW and FD diffuse 
optical measurements. 
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These representative diffuse optical systems have successfully demonstrated their 
feasibility for clinical breast cancer imaging. They were used to conduct real-time as well 
as longitudinal measurements on breast cancer patients. These technologies utilized both 
transmission and remission imaging geometries over breast tissue and achieved 
topographic and tomographic tissue functional information. However, these designs also 
has several limitations. First, they use optical fibers for light delivery to and from the 
patient. This type of design is often bulky, heavy, and fragile. Second, the optical probe 
or patient/device interface is typically rigid and poorly conforms to the natural shape of 
human tissue, which could be uncomfortable for the patient, especially during extended 
measurements. Third, for optical probes with limited number of light sources and 
detectors, a 2D mapping of tissue properties may require the probe head sequentially scan 
over gridded positions on the skin. Therefore, data acquisition for each iteration may take 
10s of minutes, and poor temporal and spatial resolution from this imaging protocol 
excludes the possibility of real time monitoring of tissue hemodynamics. 
This thesis proposes, designs, and validates a breast tissue imaging system that 
addresses the limitations described above with wearable probes. To the best of my 
knowledge, this is the very first wearables designed or used for breast measurements. 
2.8. Feasibility testing and prototype development of a CW wearable probe. 
The goal of this work was to develop the first optical wearable probe for breast 
tumor monitoring. The following sections describes component feasibility testing, 
component selection, and early prototype probe design and fabrication. It also describes 
some probe testing data that were not included in subsequent chapters due to manuscript 
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space limitations (Chapters 3 and 4 are either published or in preparation for publication). 
Chapters 3 and 4 then describe more advanced wearable probe clinical prototypes and 
relevant in vitro and in vivo testing. 
2.8.1 Selection of optical transducers 
The optical transducers for the wearable diffuse optical imaging probe were 
chosen based on several criteria. First: the cost and simplicity of the hardware design. 
During the design process it was decided that the components should be commercially 
available off-the-shelf, which helps to reduce the cost of prototype design and simplifies 
fabrication of additional probes. Economical optical transducers, such as LEDs and 
photodiodes, are the favorable candidates in this sense. Second: fitness to a wearable 
device. Light emitters and detectors with surface mount packages have a low profile, 
compact pin layout, and have durable electrical contact with flexible copper layers. 
Thirds: the optical spectrum for tissue imaging. The emission spectrum of light source 
should cover relevant NIR wavelengths, where tissue absorption is strongly affected by 
hemoglobin concentration and its changes.  
In order to address the question of wavelength selection, a condition number 
analysis was utilized to optimize the accuracy of extracting tissue hemodynamics (Corlu 
et al. 2003). The condition number 𝜅(𝐴) of a matrix that maps extinction coefficients for 
HbO2 and HHb is was used based on prior work (Corlu et al. 2003). It quantitatively 
measures the amplification of the noise from the input to the output. Therefore, optimized 
wavelength pairs correspond to a condition number close to one, which indicates 
calculations with Beer’s Law at the chosen spectrum add zero uncertainty to the changes 
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in absorbance. This is the ideal case for calculating changes in tissue chromophore 
concertation. The condition number is expressed as  
𝜅(𝐴) = ‖𝐴−1‖ ∙ ‖𝐴‖ 
where 𝐴 = (
𝜀𝜆1
𝐻𝑏𝑂2 𝜀𝜆1
𝐻𝐻𝑏
𝜀𝜆2
𝐻𝑏𝑂2 𝜀𝜆2
𝐻𝐻𝑏
) is the matrix of extinction coefficients for HbO2 and HHb at 
the chosen wavelength pair. In Figure 2.10, a contour line that represents 𝜅 = 100.5 is 
shown. The wavelength pairs that correspond to the region inside of the dashed line were 
considered to be the best choices for extractions of HbO2 and HHb changes. 
 
Figure 2. 10 Condition number of the matrix of extinction coefficients  
Based on the condition number analysis as well as the other criteria described 
above, the following LEDs were chosen as optical sources for the wearable probe: 
SMT750-23 and SMT850-23. Both of these LEDS are in the PLCC-2 package and 
manufactured from Roithner Lasertechnik. Their central wavelengths are 750 nm and 850 
(14) 
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nm, respectively. Two different photodetectors were considered for the wearable probe: 
the S4797-01, a Si photodiode made from Hamamatsu Photonics, and the TSL250RD-
TR, an 8-SOIC Si light-to-voltage sensing module made from TAOS Inc. Both have 
relatively high responsivity at the LED wavelengths. Figure 2.11 shows the responsivity 
of the TSL250RD-TR. 
 
Figure 2. 11 Responsivity of Si sensing module 
2.8.2 Validation of LED - photodiode pairs 
A rigid printed circuit board (PCB) was designed and fabricated to test and 
validate the LEDs and the first photodiode (S4797-01, Hamamatsu Inc.). This test 
platform is shown in Figure 2.12. It contains six pairs of LEDs and one photodiode. The 
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layout of these optical transducers is based on previous design for breast tissue imaging, 
which places light sources onto the corners of a hexagon, while the detector is centered 
within this geometry (Chance et al. 2005). The source-detector optode separation is 25.4 
mm and is similar to the set up in our frequency domain DOSI imaging system (Cerussi 
et al. 2006). 
 
Figure 2. 12 Optical probe of first generation diffuse optical imaging system 
The rigid optical probe was initially tested using a tissue-simulating solid silicone 
phantom. A diagram of a phantom measurement layout is shown in Figure 2.13. The 
collected photocurrent was conditioned with a transimpedance amplifier (TIA) before 
data acquisition with a 16-bit DAQ board (USB-6361, National Instruments). 
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Figure 2. 13 Diagram of the rigid probe testing platform. Green shown the rigid 
PCB containing 12 LEDs and one photodiode. 
Unfortunately, electrical noise strongly contaminated the transducer signal in this 
design. This was due to electromagnetic interference with the tiny photocurrent from the 
photodiode. To solve this problem, the S4797-01 photodiode was replaced with the 
TSL250RD-TR (TAOS Inc), which contained an integrated TIA within the detector 
package. Additionally, the optical signals were modulated at 1 kHz and the detected  
signal was passed through an analog band-pass filter to reduce noise. Additional design 
details of this source-detector pair are included in Chapter 3. 
Validation of this new optode configuration was performed by fabricating a pair 
of small rigid PCBs for the LEDs and detector. The benefit of this design is that the 
source-detector separation can be adjusted freely through a wide range. The separation of 
light source and detector was tested from 21 mm to 49 mm. This range roughly 
corresponds to the range of advanced breast tumor diameters (Elkin et al. 2005). The 
system linearity was evaluated at each source-detector separation from phantom 
measurements by adjusting the LED forward current. In addition, dark measurement 
result, which is taken with a piece of black rubber, was compared with the phantom 
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measurements to quantify the signal to noise (SNR) level.  
Figure 2.14 shows the results from the linearity testing. The data indicate 
excellent system linearity from 10 mA to 90 mA for most measurements, although 
detector saturation was a problem for short optode separations (less or equal to 20 mm). 
For longer optode separations, the collected signal was greater than the background noise 
by at least one order of magnitude. These results indicate that this transducer pair is 
promising for tissue optical measurements over a wide range of optode separations. 
 
Figure 2. 14 Validation of single source and detector module with respect to 
different separations and forward current. Left: Measurements at 850 nm. Right: 
Measurements at 750 nm. 
The LEDs and photodiode package described above were used for the wearable 
prototypes described in the following chapters. 
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CHAPTER 3. GENERATION II CW DIFFUSE OPTICAL SPECTROSCOPIC 
IMAGING SYSTEM 
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3.1 Introduction 
Optical wearables may provide new opportunities for tracking healthy and disease 
states longitudinally, including time points currently unobtainable with standard-of-care 
clinical imaging modalities. Superficial-probing wearable optical heart rate monitors are 
widely available in the consumer space for fitness tracking, but there has been 
substantially less development in the medical space for deep tissue applications in 
oncology. We present here a new diffuse optical wearable probe, designed to track tumor 
metabolism and hemodynamic changes during breast cancer chemotherapy treatment. 
This new imaging platform may allow for the identification of important new prognostic 
timepoints that can be used to modify treatment and drug regimens for individual 
patients. 
The optical measurement of tumors in the breast typically requires the 
measurement of multiply-scattered near-infrared (NIR) light which has traveled up to 
several centimeters in depth. Due to the diffusive nature of photon propagation in thick 
biological tissue, techniques that employ these measurements are usually referred to as 
Diffuse Optical Imaging (DOI) or Diffuse Optical Spectroscopy (DOS).(Jacques and 
Pogue 2008) These methods have been widely shown to be capable of extracting tissue 
level concentrations and/or changes in concentration of key functional parameters in the 
breast, brain, muscle, and other tissues. Depending on wavelengths utilized, the 
parameters may include oxyhemoglobin, deoxyhemoglobin, water, and lipids.(Choe and 
Durduran 2012) Diffuse optical techniques can be broadly classified into three variants: 
continuous wave (CW), frequency-domain (FD), and time-domain (TD) methods. FD and 
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TD techniques provide separation of optical absorption and scattering effects, but 
typically require modulated or pulsed laser sources and sensitive avalanche photodiodes 
(APD) or photomultiplier tube (PMT) detectors.(Pogue et al. 1997; Pham et al. 2000; Yu 
et al. 2003) CW techniques can provide relative changes in tissue chromophores if 
assumptions or prior knowledge of the wavelength dependence of scattering are 
available.(Gao et al. 2011) In situations where the optical scattering can be assumed to be 
time-invariant, CW DOI or DOS can be used to monitor hemodynamic and metabolic 
changes in tissue with relatively simple instrumentation and analysis techniques. This is 
especially relevant over short time periods (seconds to hours).(Benni et al. 2005; Coyle, 
Ward, and Markham 2007; Tisdall et al. 2009) Measurements are possible with 
inexpensive LEDs and photodiodes, and surface-mount packaging of these components 
reduces the device footprint and facilitates the design of flexible optical probes that can 
be used in direct contact with skin. These features provide the possibility for wearable 
CW imaging probes for measurements of deep tissue hemodynamics. Several optical 
wearables have been previously developed and applied for studies related to 
cardiology,(Stojanovic and Karadaglic 2013) general purpose blood oxygen 
saturation,(Muehlemann, Haensse, and Wolf 2008; Stojanovic and Karadaglic 2013) and 
cerebral activity,(Muehlemann, Haensse, and Wolf 2008; Atsumori et al. 2009; Piper et 
al. 2014; McKendrick, Parasuraman, and Ayaz 2015; Pinti et al. 2015) but we know of no 
prior work in optical wearables for tumor chemotherapy monitoring. 
Prior DOI and DOS instrumentation, which include both largely immobile 
platforms and more portable handheld probes, have been previously utilized to monitor 
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chemotherapy response in breast cancer patients receiving neoadjuvant (presurgical) 
chemotherapy. FD techniques,(Shah et al. 2001b; Zhou et al. 2007; Cerussi et al. 2010; 
Roblyer et al. 2011; Ueda et al. 2012; Jiang et al. 2014) TD techniques,(Torricelli et al. 
2003; Spinelli et al. 2005; Taroni et al. 2010; Falou et al. 2012) and CW techniques 
(Flexman et al. 2011, 2013; Anderson et al. 2015) have been employed to track tumor 
hemoglobin, water, and lipid changes throughout treatment. Most prior studies have been 
focused on changes in tissue chromophore concentrations after weeks of treatment. For 
example, Cerussi et al. showed that, by comparing the functional properties between 
tumor and normal tissue, breast cancer patients who achieved pathologic complete 
response to neoadjuvant chemotherapy had a 23% reduction in total hemoglobin on 
average by the midpoint in treatment compared to a 11% reduction in partial and non-
responders.(Cerussi et al. 2011) Other groups have shown similar trends.(Zhu et al. 2008; 
Soliman et al. 2010; Busch et al. 2013; Jiang et al. 2014) Recently, it was reported that 
changes in oxyhemoglobin concentration on the first day after an initial chemotherapy 
infusion could statistically differentiate responders from non-responders.(Roblyer et al. 
2011) We hypothesize that hemodynamic changes during the first chemotherapy infusion 
(typically lasting several hours) may also be prognostic of long-term treatment response. 
A new wearable CW DOI probe is presented here which was designed to monitor these 
very early time points. The performance of the probe was evaluated in vitro using tissue-
simulating phantoms and in vivo with a cuff occlusion test.  Additionally, a normal 
volunteer was measured continuously over a period of 10 minutes to evaluate the stability 
and comfort of the probe.  
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3.2 Instrument Design  
The CW wearable probe was designed to be flexible in order to accommodate the 
natural curvature of human breast tissue. Figure 3.1(a) shows the flexible printed circuit 
board (PCB) with optical and electrical components. The flexible PCB was fabricated 
with two mil (51 µm) copper and polyimide. From the central hub of the wearable probe, 
six flexible arms radiate and form into the backbone of a hexagon. Each arm has an LED 
pair at its terminal end; the seventh arm terminates with a micro-HDMI connector.  A 
photodiode module is positioned at the central hub. 
The surface mount LED pairs (SMT750-23 and SMT850-23, Roithner 
Lasertechnik) have a peak emission wavelength of 750 nm and 850 nm, and each 
generates a total optical output power of approximately 20 mW at a 50 mA forward 
current.(Eggebrecht et al. 2014) The optical detector module (TSL250RD, ams AG) has a 
1 mm active area photodiode with an integrated transimpedance amplifier with an 
irradiance responsivity of approximately 74 mV/(µW/cm2). The source-detector 
separation between the LEDs and the photodiode is 25.4 mm. Similar source-detector 
separations have been shown to provide adequate optical depth penetration for 
measurements of most breast tumors eligible for neoadjuvant chemotherapy. (Benni et al. 
2005; Izzetoglu et al. 2005; Cerussi et al. 2007; Roblyer et al. 2011)  A thin plastic 
stiffener was fabricated to add rigidity from the central hub to the 7th radiating arm, 
which serves as the cable connection point. A 19-pin micro HDMI cable is used to 
communicate between the wearable probe and benchtop control electronics. Figures 
3.1(b) and 3.1(c) show the completed probe. A hexagonal medical grade silicone housing 
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encapsulates the probe and has a dimension of 90.7 mm between the opposite vertices. 
The maximum thickness of the encapsulated probe is 11.3 mm, and it has a total mass of 
48.9 grams. The probe is highly flexible along all dimensions except the dimension 
parallel to the HDMI cable due to the plastic stiffener (Fig 3.1(d)).  
 
Figure 3. 1 (a) Flexible PCB and optical components. (b) Top and (c) bottom view of 
the wearable probe. (d) Flexibility of the probe under gentle pressure. 
Figure 3.2 shows a block diagram of the probe and control electronics. A data 
acquisition board (National Instruments USB-6361) provides a low frequency sinusoidal 
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analog signal as a modulation input to the current controller (ILX Lightwave, LDX-
3525B), which in turn provides the forward current to the LEDs with a modulation index 
of 0.9. The forward current is modulated at 1 KHz to assist in rejection of background 
noise, 60 Hz electrical noise and harmonics, and to match the response from the 
photodetector. A 4-bit digital control signal is also generated by the DAQ to control the 
sequence of LED illumination. Digital and analog signals are delivered to the probe 
through an HDMI cable. The digital lines are fed into a 4-to-16 line decoder 
(74HC/HCT4514, Philips Semiconductors) which direct the current into individual LEDs 
through a bank of MOSFET switches. On the detection side, the photodiode provides a 
linear response to light intensity, and photocurrent is converted to a voltage signal with 
an integrated transimpedance amplifier. The amplified signal is routed through the HDMI 
cable and is further amplified by 10 dB and filtered through a custom 1 KHz 8th order 
Bessel band-pass filter (BPF) with a 200 Hz -3dB passband width prior to data 
acquisition. The probe is controlled using a custom LabView program. 
During operation, each of the twelve LEDs is illuminated sequentially, and a 
complete measurement cycle is defined as measurements collected from all twelve 
optode pairs. Data is acquired at 100K samples per second with a sampling length of 50 
ms for each optode. Due to the delay from BPF settling time, and other optical and 
electronic components, a 35 ms delay was added between optode measurements. A 
complete measurement cycle takes 1020 ms (85 ms x 12). A delay can be added between 
measurements cycles depending on desired experimental conditions.  
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Figure 3. 2 Schematic view of CW diffuse optical imaging system. Solid line: 
electrical signal. Red arrow: optical signal 
3.3 Instrument Performance 
Initial performance testing was conducted using tissue simulating silicone solid 
phantoms and blood-intralipid based liquid phantoms.  
3.3.1 Signal to Noise Ratio (SNR), Dynamic Range, and System Crosstalk  
The system voltage outputs were processed using a Fast Fourier Transform (FFT) 
with a rectangular window to compute SNR and dynamic range. Power measurements of 
the signal-of-interest were summed over a 500 Hz band centered at 1 KHz in the FFT, 
and DC and the first ten harmonics were excluded for these calculations. SNR and 
dynamic range were calculated as 10log(Psignal/Pnoise).  SNR measurements were taken 
on a set of three breast-like tissue-simulating solid phantoms with the following optical 
properties: phantom 1: μa = 0.0054 mm-1 (750nm), μa = 0.0038 mm-1 (850nm), μs
′  = 1.2 
mm-1 (750nm), μs
′  = 1.0 mm-1 (850nm); phantom 2: μa = 0.0045 mm-1 (750nm), μa = 
0.0032 mm-1 (850nm), μs
′  = 1.1 mm-1 (750nm), μs
′  = 0.9 mm-1 (850nm); phantom 3: μa 
= 0.0036 mm-1 (750nm), μa = 0.0026 mm-1 (850nm), μs
′  = 0.9 mm-1 (750nm), μs
′  = 0.8 
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mm-1 (850nm). These optical properties closely match prior reported normal breast tissue 
values.(Durduran et al. 2002; Shah et al. 2004) A SNR greater than 68 dB for channels 
with 750 nm LEDs, and greater than 71 dB for channels with 850 nm LEDs was achieved 
for measurement on a breast-like tissue-simulating solid phantom. The system dynamic 
range was at least 80.4dB when measuring the maximum optical signal level. During 
normal operation, it is possible that light may travel directly from source to detector 
along the tissue surface causing undesired optical source-detector crosstalk. Additionally, 
inductive coupling may cause undesired electrical crosstalk at the PCB level or in the 
HDMI cable. In order to evaluate both electrical and optical crosstalk, measurements 
were taken on a highly absorbing black phantom, and a 7 dB signal for the 750 nm LEDs, 
and 6 dB signal for 850 nm LEDs was observed at the 1 KHz modulation frequency 
relative to the average noise floor. This indicates that the crosstalk signal is at least 60 dB 
weaker than the signal from breast-like tissue phantom measurements.   
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3.3.2 System Drift 
 
Figure 3. 3 System drift test. Results are shown for (a) the 750 nm and (b) 850 nm 
optical channels. An average drift of 0.18% or less was observed over the 90-minute 
test. 
A system drift test was performed to evaluate the repeatability of the system 
under static experimental conditions. 180 repeat measurement cycles were acquired over 
90 minutes (a typical chemotherapy infusion length), and results from each source-
detector (optode) pair were normalized relative to the Root-Mean-Square value of 
modulated signal (Vrms) from the first measurement. Fig 3 shows the drift for each 
source-detector pair (each source-detector pair is identified by its probe arm in the figure 
legend). On average, an absolute system precision of 0.17% was achieved for optical 
channels with 750 nm LEDs and a precision of 0.18% was achieved for optical channels 
with 850 nm LEDs. The largest single optode drift was observed in probe arm 4, equaling 
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0.40% and 0.51% for the 750 nm and 850 nm LEDs, respectively. These results indicate 
that the probe is capable of highly repeatable measurements. 
3.3.3 Thermal Stability 
 
Figure 3. 4 System thermal response to local probe temperature changes. The red 
solid line corresponds to the local temperature measured at the probe, while the 
black solid line corresponds to the normalized changes in detector voltage levels. 
The shaded area indicates the standard derivation calculated from the optodes that 
share the same wavelength. The red dashed lines show the upper and lower bound 
of normal physiological temperature of human skin.(Olesen 1982) 
A thermal stability test was conducted in order to determine the sensitivity of the 
probe to different ambient temperatures. This is relevant as the probe will be placed 
directly against the subject’s skin, and skin temperature may change over time. A thermal 
sensor from a thermal data logger was positioned in contact with the underside of the 
probe. Five minutes of repeated measurements were taken on a solid phantom to establish 
a baseline; measurements were taken every five seconds. The local temperature of the 
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probe was controlled using a hotplate which was positioned under the optical phantom. 
The hotplate was then turned on and the probe temperature rose from approximately 
26.6°C to 39.2°C over a period of approximately 14 minutes. Figure 3.4 shows the 
thermal response of the probe for the 750 nm and 850 nm optical channels. Within a 
normal physiological temperature range(Olesen 1982) (indicated by the area between two 
horizontal dashed lines in Figure 3.4), measured voltage changes correspond to an 
average thermal response of 0.35% Vrms per degree (Vrms/°C) for the 750 nm channels 
and 0.22% Vrms per degree (Vrms/°C) for the 850 nm channels. These results indicate 
only minor fluctuations in instrument response over the expected operating temperature 
range. 
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3.3.4 Probe Accuracy  
 
Figure 3. 5 Probe results compared to a dissolved oxygen sensor for (a) oxygen 
saturation and (b) chromophore concentration changes measurements taken from a 
blood-intralipid phantom during phantom deoxygenation. 
To determine the accuracy of the wearable probe, it was tested against a 
commercial dissolved oxygen (DO) sensor (VisiFerm DO Arc 120, Hamilton Robotics), 
which served as a gold standard for this study. Measurements were taken on a blood-
intralipid based liquid phantom during dynamic oxygenation changes. The phantom was 
made by adding 17 ml of pooled bovine blood (Carolina Biological Supply Company), 48 
ml of intralipid (Fresenius Kabi, 20% I.V. Fat Emulsion), 120 ml of 10X Phosphate 
Buffered Saline (PBS) solution (Fisher Scientific), and 1015 ml of deionized water for a 
total phantom volume of 1200 ml. The phantom was contained in a 6-inch diameter 
cylindrical baking pan placed on a stirring hotplate which maintained a constant phantom 
temperature of 37°C. A magnetic stir bar was used to stir the phantom at a constant 
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spinning rate of 120 revolutions per minute.  
The phantom started near 100% oxygen saturation and was slowly deoxygenated 
by adding a solution of baker’s yeast, made by dissolving active dry yeast into deionized 
water with a concentration of 1 mg/ml. A total of 4.2 ml yeast solution was gradually 
added to the phantom which caused a change in oxygen saturation from approximately 
100% to 34% over a 43-minute period. During this time, the wearable probe and the DO 
sensor simultaneously monitored the hemodynamics in the liquid phantom. Temperature 
and pH were monitored continuously throughout the test. The DO sensor measures the 
concentration of unbound oxygen, and DO concentrations were converted to oxygen 
saturation values using a published dissociation curve for matching temperature and pH 
levels.(Kelman 1966) DO measurements were taken every five seconds over the 43 
minute period. 
The Modified Beer-Lambert Law (MBLL) was utilized to convert the raw Vrms 
measurements from the wearable probe to oxygen saturation values as well as changes in 
oxyhemoglobin and deoxyhemoglobin concentration.(Kocsis, Herman, and Eke 2006) 
Measurements of the initial optical properties of the liquid phantom were taken using an 
in-house frequency domain diffuse optical spectroscopic imaging system. The initial 
optical properties were then used to calculate a differential pathlength factor assuming a 
homogeneous semi-infinite medium:(Arridge, Cope, and Delpy 1992)  
𝐷𝑃𝐹(𝜆) =  
1
2
(
3𝜇𝑠
′(𝜆)
𝜇𝑎(𝜆)
)
1
2
[1 −
1
(1 + 𝑑(3𝜇𝑎(𝜆)𝜇𝑠′ (𝜆))
1
2
] (15) 
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where 𝜇𝑎(𝜆) and 𝜇𝑠
′ (𝜆) are the absorption and reduced scattering coefficient of diffusive 
medium, 𝑑 is the separation of source and detector on the probe. The liquid phantom had 
a total hemoglobin concentration of approximately 30.8 µM, which is estimated from 
previously reported values for bovine blood (13 to 15 g/100mL).(Fraser 1991) Changes 
from an initial value of approximately 100% oxygen saturation (as verified by the DO 
sensor) were computed and compared with values from the DO sensor. Wearable probe 
measurements were taken once every five seconds during the 43-minute period. 
Figure 3.5(a) shows the agreement between the wearable probe and the DO sensor 
for saturation values between 40% and 90%. Typical oxygen saturation levels of human 
breast tissue have been shown to be approximately 68%,(Srinivasan et al. 2006) and the 
tested range here was chosen as it is inclusive of saturation levels that meet or exceed 
those expected in human breast measurements. There is less than 5% disagreement in 
oxygen saturation measurements between the wearable probe and the DO sensor over this 
range, with an R2 value of 0.998. Figure 3.5(b) shows changes in oxyhemoglobin 
(HbO2), deoxyhemoglobin (HHb), and total hemoglobin (THb) over the 43-minute 
period. There was reasonable agreement between the wearable probe and the DO sensor 
for HbO2 changes, with a difference of 2.13 µM by the end of the test. There were 
slightly larger differences in HHb measurements, with a maximum difference of 2.84 µM 
by the end of the test.  These differences may be caused by a number of factors, including 
errors in the initial optical property estimates or small system nonlinearities.  
  
  
53 
3.4 In vivo Measurements 
3.4.1 Cuff Occlusion Test 
A cuff occlusion test was performed to demonstrate the in vivo measurement 
performance of the wearable probe. Baseline optical properties of the forearm were 
obtained from literature values.(Matcher, Cope, and Delpy 1997; Franceschini et al. 
1999) The MBLL was used to determine chromophore concentration changes as before 
with optical scattering assumed constant over the measurement. Measurements were 
taken every 1.02 seconds during the occlusion test. 
 
Figure 3. 6 (a) The probe is secured to the subject’s skin using IV tape during cuff 
occlusion measurements. (b) and (c) Hemodynamic response at forearm during cuff 
occlusion test. 
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Figure 3.6 shows continuous extractions of oxyhemoglobin, deoxyhemoglobin, 
and total hemoglobin molar concentration changes from a single source-detector pair 
during the cuff occlusion. The wearable probe was securely attached to the forearm, and 
an adult blood pressure cuff was applied to the upper arm of a healthy volunteer with no 
pressure added to the aneroid sphygmomanometer. Starting from t = 30 sec, cuff pressure 
was rapidly increased to a maximum of approximately 200 mmHg. From the 30th second 
to the 150th second, the concentration of oxyhemoglobin gradually decreased while 
deoxyhemoglobin concentration increased at a faster rate. Changes in the total 
hemoglobin concentration during this period indicate a net influx of oxygenated blood 
into the forearm, which might be due to incomplete occlusion of arterial supply. At t = 
150 sec, the cuff pressure was released, and oxygenated blood quickly refilled the 
forearm circulation, causing a rapid rise in oxyhemoglobin and total hemoglobin with a 
corresponding decrease in deoxyhemoglobin. Chromophore concentrations gradually 
returned to steady state. These observations match expectations and demonstrate the 
ability of the probe to measure hemodynamic changes in the in vivo setting.(Li et al. 
2013) 
3.4.2 Normal Volunteer Test 
As a proof of concept, a normal volunteer test was conducted on a 46 year old 
pre-menopausal woman to evaluate the feasibility of taking continuous measurement over 
healthy female breast tissue. This test was carried out under the approval of Boston 
University Institutional Review Board.  
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The wearable probe was placed on the top left corner of her left breast, with a 5 
mm distance between the wearable probe and the nipple. The HDMI cable was supported 
by placing it over the subject’s neck and the wearable probe was secured using IV tape. 
The probe was allowed a ten-minute warm-up and stabilization period prior to optical 
measurements. The volunteer was allowed to move in the chair during the measurement. 
Repeated measurement cycles were taken every 1.2 seconds. 
Figure 3.7 shows chromophore concentration changes over a ten-minute 
measurement period, which is a portion of a longer measurement. A 0.08Hz low-pass 
filter was applied to remove known physiological signals including heart beat 
(approximately 1Hz, aliased to 0.17 Hz for the sampling rate used), respiration (0.2 to 
0.3Hz) and Mayer waves (approximately 0.1Hz).(Toronov et al. 2000; Tong, Lindsey, 
and Frederick 2011; Kirilina et al. 2013) The remaining low frequency components are 
expected to contain contributions from motion as well as tissue oxygenation fluctuations 
during resting state, which typically vary on sub-minute to minute time frames.(Jiang et 
al. 2013) Prior to filtering, variations in CW signal level were generally around 5%, 
which agrees well with previously reported measurements on healthy breast tissue over a 
similar time frame.(Durduran et al. 2002) We note that motion artifacts do have the 
potential to mask or mimic underlying physiological changes in breast tissue, and 
methods to detect and remove these from the data are currently being investigated.   
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Figure 3. 7 Hemodynamic fluctuations of healthy female breast tissue at resting 
state. (a) Oxyhemoglobin (HbO2) and deoxyhemoglobin (HHb), (b) total 
hemoglobin (THb). 
3.5 Discussion 
This work demonstrated the performance of a new, deep-tissue, optical wearable 
probe designed for monitoring breast cancer patients during presurgical chemotherapy. 
Tissue-simulating phantom measurements revealed low crosstalk (-60dB), high SNR 
(71dB), high precision (0.17%), and good thermal stability (0.22% Vrms/°C). The 
accuracy of our CW measurements was evaluated with a blood liquid phantom at 
different saturation levels, which resulted in less than 5% error in oxygen saturation 
estimates. Cuff occlusion and breast measurements reflected expected tissue 
hemodynamics. 
The probe was specifically designed to monitor breast tumor oxygenation changes 
throughout chemotherapy infusions, which typically consist of one to three different 
cytotoxic and/or targeted agents sequentially infused intravenously of a period of several 
hours. There are several application specific considerations that affected the design of 
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this probe and ultimately differentiate it from other ambulatory and wearable diffuse 
optical devices that have been developed for monitoring cerebral or muscle oxygenation.  
First, the probe was designed to be highly flexible to conform to the natural breast tissue 
shape while still being housed in a single unit with static optode geometry in order to 
enable measurement comparisons between subjects.  Additionally, although the 
investigation of chemotherapy induced changes during infusions is an emerging area of 
research, it is expected that substantial hemodynamics will likely change over timescales 
of minutes to hours, substantially slower than the timecourse of cerebral evoked potential 
or functional activations typically observed in the brain, or muscle contraction and 
relaxation observed for fitness monitoring applications. This relaxes the requirement for 
rapid measurement speeds often sought for other DOT applications, but increases the 
need for stable and repeatable measurements over long time periods. Our design was 
shown to provide highly stable measurements during phantom experiments, and only 
small fluctuations were observed during the normal breast measurement, but the issue of 
motion artifact reduction must be properly addressed prior to implementation in the 
clinical setting. We are currently exploring better ways of stabilizing the probe on the 
breast along with signal processing approaches for removing these artifacts from the data. 
It is of note that the largest change from baseline in HbO2 concentration observed during 
the normal volunteer measurements in this study was approximately 8% over a 10 minute 
period. In comparison, changes of approximately 20 to 40% in HbO2 were observed after 
the first 24 hours in patients receiving neoadjuvant chemotherapy in a prior 
study.(Roblyer et al. 2011) In the future, a normal volunteer study will be conducted to 
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better identify the magnitude of natural physiological variations in breast hemodynamics 
during multi-hour measurements in order to better understand how continuous 
measurements may be able to track treatment response. 
To the best of our knowledge, this CW imaging system is the first demonstration 
of a wearable device aimed at continuously monitoring the hemodynamic response from 
breast cancer patients and represents a promising new tool to target unexplored 
prognostic timepoints during neoadjuvant chemotherapy infusions. 
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4.1 Introduction  
Locally advanced breast cancers (LABC) are breast tumors that are large (>2 cm), 
may have a direct extension to the skin or chest wall, or present with regional metastasis 
to lymph or mammary nodes (Garg and Prakash 2015). LABC presents at least three 
substantial challenges to clinical treatment. First, the 5 year overall survival rate for 
LABC patients can be as low as 76% even after a combination of surgery, radiotherapy 
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and chemotherapy (SEER Cancer Statistics Review 2018). Second, with traditional 
treatment procedures most subjects have to endure mastectomy, which aggressively 
removes the entire affected breast and axillary lymph nodes (Steligo 2017). Third, some 
primary breast tumors may not be resectable as the cancer invades the skin or chest wall 
(Garg and Prakash 2015). 
To overcome these challenges, preoperative chemotherapy, also called 
neoadjuvant chemotherapy (NAC), was introduced to shrink tumor size before surgery. 
NAC has been increasingly adopted as the default treatment plan for LABC patients 
(Ragaz, Band, and Goldie 2012). The pathological outcome to NAC, proposed by the 
American Joint Committee on Cancer (AJCC), is staged as complete response (pCR): 
absence of invasive carcinoma in the breast and node, partial response (PR): downgrade 
in either or both tumor (T) or node (N) stage, and no response (NR): stable or increase in 
either or both T or N stage (AJCC 2017). Approximately 10% of LABC patients achieve 
pCR, 60% PR, and 30% NR, even after weeks to months of treatment. Some patients may 
even develop progressive disease during NAC (Kuerer et al. 2000; Esserman 2004; Keam 
et al. 2013). Therefore, the prediction of patients’ response to NAC at earlier timepoints 
based on tissue anatomic or functional imaging could be highly valuable in optimizing 
the treatment plan and maximizing outcomes.  
Several traditional clinical imaging methods have been explored for breast cancer 
monitoring during the course of NAC. For example, positron emission 
tomography/computed tomography (PET/CT) using fluorine-18-fluorodeoxyglucose 
(18F-FDG) has been reported to predict patients’ response with about 80 - 90% accuracy 
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(Schelling et al. 2000; Chen et al. 2004; Biersack, Bender, and Palmedo 2008). Magnetic 
resonance imaging (MRI) and functional MRI have both demonstrated prognostic value 
for NAC (Esserman et al. 1999; Heldahl et al. 2011; Rigter et al. 2013; Dave et al. 2017).  
Ultrasonography and mammography have both been studied for NAC monitoring, but 
their prognostic accuracy is not comparable to the imaging modalities mentioned above 
(Tadayyon et al. 2016; Gu et al. 2017; Nam et al. 2017). 
Unfortunately, these clinical imaging modalities are accompanied by high 
expense, lack of portability, and/or safety issues due to the use of ionizing radiation or 
exogenous contrast agents. In contrast, diffuse optical imaging, which utilizes near 
infrared light and portable imaging platforms, avoids these limitations. Previous studies 
with these diffuse optical instruments have demonstrate that the pathological response of 
LABC patients to neoadjuvant chemotherapy can often be determined within weeks to 
months after the start of treatment, and are typically associated with a decrease of 
hemoglobin concentration and water content, and an increase of lipid concentration 
(Cerussi et al. 2007; Jiang et al. 2009; Choe and Durduran 2012). Recently, the acute 
response (first hours to days of treatment) to NAC has also been shown to manifest 
through significant difference between responders and non-responders when monitored 
with diffuse optical instruments. For example, in a study of 23 LABC subjects, tissue 
oxyhemoglobin concentration was determined to discriminate the pathological outcome 
from chemotherapy on the very first day after initial infusion (Roblyer et al. 2011). 
Confirmation of chemotherapy response this early during treatment could substantially 
minimize treatment burden and avoid ineffective chemotherapy. 
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This work aimed to address several unmet needs of existing breast cancer diffuse 
optical monitoring devices. First, previous designs typically deliver light to and from the 
patient using optical fibers. This type of design is often bulky, heavy, and fragile. Second, 
the optical probe or patient/device interface is typically rigid and poorly conforms to the 
natural shape of human tissue. This is limiting as it may be uncomfortable for the patient, 
especially during extended measurements. Third, for optical probes with limited number 
of light sources and detectors, a 2D mapping of tissue properties may require the probe 
head to be sequentially scanned over gridded positions on the skin (Roblyer et al. 2011). 
Therefore, data acquisition for each iteration may take 10s of minutes, and poor temporal 
and spatial resolution excludes the possibility of real time monitoring of tissue 
hemodynamics. 
In order to address these limitations, a new wearable diffuse optical probe was 
designed and fabricated to investigate if very early timepoints during a patient’s first 
NAC infusion are predictive of overall response (pCR versus non-pCR). These 
timepoints correspond to an already scheduled patient visit and have so far been 
unexplored for their prognostic value. A breath-hold was used to evaluate the vascular 
performance of breast and tumor tissue in normal volunteers and breast cancer patients as 
this hemodynamic challenge has been recently shown to be useful for monitoring NAC 
response (Flexman et al. 2013).  
4.2 Methods 
A wearable probe was designed to monitor locally advanced breast tumors during 
the course of neoadjuvant chemotherapy. Factors considered in the design include the 
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tissue depth and sizes of locally advanced breast tumors, the near infrared absorption and 
scattering properties of human breast tissue, and the anticipated changes expected to 
occur during a hemodynamic challenge, in this case a breath hold. Design choices and 
methods are described below. 
4.2.1 Wavelength selection 
The probe was designed to extract oxyhemoglobin (HbO2) and deoxyhemoglobin (HHb) 
changes during a hemodynamic breath hold challenge. The choice of imaging 
wavelengths was determined in part by a condition number analysis previously shown to 
be useful for optimizing wavelength selection (Corlu et al. 2003). The condition number 
𝜅(𝐴) is defined as   
𝜅(𝐴) = ‖𝐴−1‖ ∙ ‖𝐴‖ 
where 𝐴 = (
𝜀𝜆1
𝐻𝑏𝑂2 𝜀𝜆1
𝐻𝐻𝑏
𝜀𝜆2
𝐻𝑏𝑂2 𝜀𝜆2
𝐻𝐻𝑏
), and each element of the matrix are the optical extinction 
coefficients for HbO2 and HHb at the chosen wavelength pair. Optimized wavelength 
pairs correspond to a condition number closer to one. Dual wavelength pairs in the near 
infrared (NIR) wavelength band from 600 to 900 nm were tested using condition number 
analysis. 
4.2.2 Optode Topology 
The imaging probe was designed to measure the most prevalent tumor size ranges 
based on current epidemiological data, with a target range of 2 to 4 cm in diameter, which 
represent the 34 and 74 percentiles of locally advanced breast tumors sizes (Elkin et al. 
(16) 
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2005).  An overall probe diameter of 60 mm was chosen for all designs to accommodate 
a large range of tumor sizes. 
The probe was designed with an array of optical sources and detectors; the surface 
topography of these components directly affects the probed tissue volume. Three optode 
topographies were considered and compared using Finite Element Method (FEM) 
simulations of a breast tumor hemodynamic challenge. The topographies are shown in 
Figure 4.1 and included a “12 pointed star” pattern, a “rectangular” pattern, and a “central 
rectangular” pattern. The “12-pointed star” pattern was an extension of our prior probe 
design which utilized a central hub with arms radiated outward (Teng et al. 2017). Both 
the rectangular and central rectangular topographies have been utilized in prior 
tomographic NIRS systems for neuroimaging applications (Khan et al. 2012; Perdue, 
Fang, and Diamond 2012; Eggebrecht et al. 2014; Li et al. 2016). 
 
Figure 4. 1 Optode geometries. Left: 12-pointed star. Middle: Rectangular 
geometry. Right: Central rectangular geometry 
Each probe optode topology was tested using Nirfast, a Matlab software suite that 
utilizes FEM for numerically solving the photon diffusion equation. A tumor-like 
inclusion was modelled on a homogeneous background and incremental increases and 
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decreases in the inclusion absorption were simulated to mimic the hemodynamic 
perturbations anticipated from a breath hold challenge. Figure 4.2 shows the simulation 
geometry. The background HbO2 and HHb concentrations were set to 5.2 M and 15.6 
M, respectively, and were based on previously reported healthy breast tissue properties 
(Shah et al. 2004). The inclusion was a 35 mm diameter sphere at a depth of 5 mm.  
 
Figure 4. 2 Simulation geometry utilized for optode configuration comparisons. The 
inclusion mimics a 35 mm diameter breast tumor embedded in healthy breast tissue. 
HbO2 was incremented or decremented by 3, 6, 9 and 12 M and HHb was incremented 
or decremented by 1, 2, 3, or 4 M. The magnitude of these changes roughly corresponds 
to the documented changes of chromophore concentrations for locally advanced breast 
tumors on the day one after their initial NAC infusion (Roblyer et al. 2011). The 
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reconstructed changes in HbO2  and HHb concentrations were compared with the ground 
truth for all simulations. Crosstalk between reconstructed HbO2  and HHb was also 
evaluated. Scattering was assumed to be homogeneous and set to a wavelength-
insensitive constant of 1 mm-1 for all simulations.  
4.2.3 Printed circuit board (PCB) design 
The probe is shown in Figure 4.3. It was fabricated using a four-layer rigid-flex 
PCB design. Nine rigid PCB “islands” are connected through 0.9 mm flexible 
connections that allow flexion between rigid neighbors. The bottom copper layer (shown 
in Figure 4.3 (a)) is populated with several I2C compatible integrated circuits including an 
LED switch (MAX6964, Maxim Integrated), a bus buffer (PCA9600, NXP 
Semiconductors), and two analog multiplexers (MAX14661, Maxim Integrated). 
Additionally, MOSFET arrays (SSM6N43FU, LF, Toshiba) are used to sequential switch 
each LED. The middle layers of the PCB sit at the interface between the rigid and 
flexible substrates and facilitate trace routing. 
The top copper layer (shown in Figure 4.3 (b)) is populated with 32 LEDs (qty 16 
SMT750-23 and qty 16 SMT850-23, Roithner Lasertechnik) and 16 optical detectors 
(TSL250RD, ams). The LEDs are surface mount PLCC-2 packages with 750 nm and 850 
nm center wavelengths. The detector is an 8-SOIC silicon photo detector module with a 
built in transimpedance amplifier, the maximum responsivity of this sensing module is 
76.8𝑚𝑉/(𝜇𝑊/𝑐𝑚2) at 770 nm.  
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Figure 4. 3 (a) Bottom and (b) top view of rigid-flex PCB. (c) Top and (d) bottom 
view of the potted wearable probe. 
The wearable probe communicates with a peripheral control box through a HDMI 
cable. LEDs and detectors are sequentially selected using I2C compatible multiplexers 
and microprocessors. Amplified photodiode voltage was measured with a 16-bit analog to 
digital converter (USB-6361 OEM, National Instruments).  
4.2.4 Biocompatible probe housing 
The probe is designed to conform to the curved surface of breast tissue, and is 
potted and cured in a medical grade silicone housing. Figures 4.3(c) and 4.3(d) show the 
top and bottom sides of the probe encased in housing. It is made with skin-safe silicone 
(Ecoflex 00-30, Smooth-On Inc.) and pigments (Silc Pig, Smooth-On Inc.). The silicone 
10mm 
(a) (b) 
(c) (d) 
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and curing agent and mixed with the flesh color dye, vacuumed, transferred to a 3D 
printed mold, further vacuumed and then cured. A black silicone layer is used on the 
bottom surface of the probe to reduce light crosstalk from emitters to detectors. The 
optical emitters and detectors protrude from the silicone surface by approximately 0.3 
mm and indent the soft tissue of the breast. The total dimension is 79.4 mm wide and 9.6 
mm thick, and its overall weight is 41.8 grams. IV tape firmly secures the silicone probe 
over the curved surface of bust model as shown in Figure 4.4.  
 
Figure 4. 4 Wearable probe attached to the curved surface of human bust model. 
4.2.5 System characterization 
The SNR of each source-detector optode pair was evaluated using a custom 
silicone tissue-simulating phantom. The optical properties of the phantom closely match  
reported healthy breast tissue values (Durduran et al. 2002; Shah et al. 2004). These 
optical properties were confirmed using a benchtop frequency domain diffuse optical 
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spectroscopy system (Torjesen, Istfan, and Roblyer 2017), and were measured to be: 
𝜇𝑎 = 0.0036 𝑚𝑚
−1 (750 nm), 𝜇𝑎 = 0.0026 𝑚𝑚
−1 (850 nm) and 𝜇𝑠
′ = 0.9 𝑚𝑚−1 (750 
nm), 𝜇𝑠
′ = 0.8 𝑚𝑚−1 (850 nm). 
The SNR of each optode was calculated as: 
20 ∙ 𝑙𝑜𝑔10 (
𝑉𝑏 − 𝑉𝑑
𝑠𝑡𝑑(𝑉𝑏 − 𝑉𝑑)
) 
where 𝑉𝑏 and 𝑉𝑑 are the mean of the DC voltage collected for phantom and dark 
measurements respectively. Dark measurements were taken with the LEDs off. All 
measurements were taken under ambient fluorescent lighting. A custom black rubber 
sheet was utilized to block light leakage from neighboring optodes for SNR 
measurements as they were taken on rigid flat phantom. 
 The system dynamic range was computed as a combination of the dynamic range 
of the 16-bit ADC (96 dB) and the operating range of the LEDs (26 dB). System 
precision was evaluated by computing the standard derivation of phantom measurement 
taken over a continuous two-hour period. The acquisition speed of the probe was 
determined by recording the time necessary to sequentially scan 408 optodes (the shortest 
source-detector optodes were excluded).  
4.2.6 Channel phantom for simulated breath hold tumor hemodynamics 
A dynamic channel phantom was fabricated to mimic an embedded inclusion 
(tumor) with changing hemoglobin levels. Figure 4.5 (a) shows the phantom geometry 
and Figure 4.5 (b) shows the fabricated phantom. This channel inclusion has a diameter 
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of 35 mm and it is 5 mm deep from the top air-phantom interface. These dimensions 
match the diameter of a common locally advanced breast tumor (Elkin et al. 2005). The 
solid silicone phantom was fabricated using titanium dioxide and nigrosin to control 
optical scattering and absorption respectively. Optical properties were validated using a 
frequency-domain diffuse optical spectroscopy system (Torjesen, Istfan, and Roblyer 
2017). Measured reduced scattering coefficients are 𝜇𝑠
′ = 0.78/𝑚𝑚 and 𝜇𝑠
′ = 0.67/𝑚𝑚 
at 750 nm and 850 nm, respectively. Measured absorption coefficients at the same 
wavelength pair are 𝜇𝑎 = 0.043/𝑚𝑚 and 𝜇𝑎 = 0.0028/𝑚𝑚. 
 
Figure 4. 5 (a) Channel phantom geometry. (b) Unfilled and (c) filled channel 
phantom.  
The channel was filled with an intralipid-based liquid solution to mimic tumor 
optical properties as shown in Figure 4.5 (c). The liquid phantom utilizes a 20% fat 
emulsion which was diluted with deionized water to adjust optical scattering. Five 
different liquid phantom batches were prepared. The first was fabricated to match the 
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absorption and reduced scattering of the solid phantom. The others had 25%, 50%, and 
100% increases in 𝜇𝑎. These five batches were sequentially filled and drained from the 
channel and used to validate the ability of the wearable probe to detect changes in depth 
resolved optical absorption.   
4.2.7 Normal volunteer breath hold study 
All human subject measurement procedures were approved by Boston University 
institutional review board. A set of two wearable probes were placed on the top half of 
each breast of each volunteer (one probe per breast). The two probes were placed in 
mirror symmetry, and each was secured with an intravenous transparent dressing. A 
female volunteer was recruited to perform three repeat breath holds. Each breath hold 
measurement consisted of a 30 second system warm-up, followed by five iterative dark 
measurements, then one minute of baseline measurements, 30 seconds of breath hold 
measurements, two minutes of breath release measurements, and then at least two 
minutes of rest before the next breath hold. 
4.2.8  Rise time and fall time calculations during breath hold 
The human measurement protocol was designed to measure a hemodynamic 
breath hold challenge in breast tumors. Prior work has demonstrated that changes in HHb 
concentration during the course of breath hold and release can be described in terms of 
modified RC circuit step response functions as shown in here: (Flexman et al. 2013)  
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𝑓(𝑡) =
{
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where 𝑡𝑝 corresponds to the time when a maximum positive change in HHb occurs and 𝑡𝑟 
and 𝑡𝑝 are the rise and fall time of this piecewise function. Normal volunteer data 
collected as part of this study were fit to these functions. The rise and fall time 
coefficients were fitted using the built in Trust-Region algorithm in MATLAB, with 
initial values chosen at 10.    
4.2.9 Effect of system acquisition speed on the accuracy and precision of fall time 
calculations  
The maximum acquisition speed of two wearable probes operating in tandem is 
approximately 0.2 Hz. This speed was determined by taking 408 unique optode 
measurements per probe. Finite switching, settling, and acquisition times for each optode 
contribute to this measurement rate. As one of the goals of the study was to extract fall 
times from breath hold data, an analysis was conducted to ensure that this acquisition rate 
provides both accurate and precise extractions. Simulated rise and fall HHb time traces 
were generated using Equation 17. Previously reported fall time coefficients were utilized 
for different breast tissue types; healthy tissue: 15s; benign: 25s; malignant: 30s (Flexman 
et al. 2013). The simulated data corresponded to a 1 Hz sampling rate, and was 
downsampled to 0.5 Hz, 0.33 Hz, 0.2 Hz, and 0.1 Hz to simulate slower acquisition rates. 
(17) 
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Gaussian white noise (GWN) was added to the simulated data sets. Noise characteristics 
were estimated by fitting an experimentally measured HHb healthy volunteer data set 
collected at 3 Hz using an earlier low-optode density probe prototype to equation 17 
(Teng et al. 2017). The standard deviation of the fit residuals was used as the standard 
deviation of the GWN and 1000 separate noise sets were generated. Each set added to the 
simulated time trace data, and rise and fall times were extracted. The distribution of these 
fit time constants was then determined at different acquisition rates to evaluate how lower 
sampling rates degrade fall time extraction accuracy and precision.   
4.2.10 Tomographic reconstructions  
Tomographic reconstructions were conducted for both phantom and healthy 
volunteer data. The first order optodes were excluded for all reconstructions due to signal 
saturation, leaving 408 optical channels for every measurement. Channels with signal 
levels less than 10 dB above the noise floor were excluded from image reconstruction. 
The Rytov approximation was used for all reconstructions, and is shown here:  
𝛷 = 𝛷0 ∙ 𝑒𝑥𝑝(𝛿𝜃) 
where Φ0 and Φ indicate the fluence rate measured with baseline and perturbed optical 
properties, respectively. For iterative measurements, the perturbation of media optical 
properties from the 𝑘th to the 𝑘+1th measurement leads to the following expression: 
𝛿𝜃 = 𝑙𝑛 (
𝛷𝑘+1
𝛷𝑘
) 
The ratio of fluence rates can be replaced with the ratio of measured voltages:  
(18) 
(19) 
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𝛿𝜃 = 𝑙𝑛 (
𝑉𝑘+1
𝑉𝑘
) 
𝛿θ is linearly correlated with spatial variations in media optical properties:  
𝑙𝑛 (
𝑉𝑘+1
𝑉𝑘
) = 𝐽𝑘 ∙ ∆𝜇𝑘 
where ∆μk represents the change in a media optical property, and J is the Jacobian matrix, 
which describes the mapping of media optical property changes to surface measurements. 
Assuming 𝜇𝑠
′  is time-invariant, the elements of J are expressed as:  
𝐽𝑘 =
(
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where 𝑖 and 𝑗 indicate the optode pair and node inside the simulation volume. 
Reconstruction of the subsurface optical property changes requires calculating the 
pseudoinverse of 𝐽𝑘, which can be expressed as 
𝐽𝑘
+ = (𝐿−1)𝑇(?̃?𝑇?̃? + 𝛼 ∙ 𝑑𝑖𝑎𝑔(?̃?𝑇?̃?))−1𝐽𝑘 
where ?̃? = 𝐽𝑘 ∙ 𝐿, and 𝐿 is the Tikhonov regularization matrix (Boas, Gaudette, and 
Arridge 2001; Eggebrecht et al. 2014). The changes in the media optical properties can 
then be computed as:  
(20) 
(22) 
(21) 
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∆μ𝑘 = 𝐽𝑘
+ ∙ ln (
V𝑘+1
V𝑘
). 
4.3 Results 
4.3.1 Wavelength selection 
Figure 4.6 shows the results of the condition number analysis for different 
wavelength pairs.  A black-dashed contour line is shown for a relatively small condition 
value of 101/2. 750 nm and 850 nm LEDs were chosen for the wearable probe based on 
their relatively small condition number (3.1) as well as commercial availability. 
  
Figure 4. 6 Condition numbers associated with wavelength pair selections. The 
dashed isoline indicates 𝟏𝟎𝟎.𝟓. The condition number corresponding to 750 nm and 
850 nm is shown with the red dot markers. 
(23) 
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4.3.2 Optode geometry validation 
Reconstructed chromophore changes were calculated within the 3D inclusion 
volume for FEM simulations conducted with each optode geometry. Results are shown in 
Figure 4.7. Results were similar for each geometry with 35% to 40% of target changes 
recovered. A 6 – 12 % crosstalk was observed between HHb and HbO2. The “central 
rectangular” pattern was chosen for the probe design because of the equivocal simulation 
results and because of its relative ease of fabrication. This design has 7 source-detector 
separation orders, ranging from 10.0 to 53.9 mm. There is a total of 512 separate optodes 
(i.e., source-detector pairs).  
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Figure 4. 7 Tomographic reconstruction results from various simulated 
chromophore perturbations in an embedded inclusion (tumor). Simulation ground 
truth is indicated on the y-axes and reconstructed values are indicated on the x-axis. 
(a) Reconstructed changes in HbO2 and HHb for perturbations in HHb. (b) 
Reconstructed changes in HbO2 and HHb for perturbations in HbO2. 
4.3.3 System performance 
SNR results are shown in Figure 4.8. LED forward current was reduced for the 
shortest optodes to avoid saturation. SNR was at least 29 dB for all separations. At each 
separation, SNR varied by as much as 20 dB, likely due to differences in optical coupling 
between the optical transducers and phantom.  
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Figure 4. 8 Signal to noise for probe source-detector separations.  
Other system characteristics are shown in Table 4.1. Thermal characteristics and 
accuracy are cited from our prior work (Teng et al. 2017). 
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Table 4. 1 System characteristics of high density wearable imaging system 
4.3.4 Channel phantom results 
Figure 4.9 shows ∆𝜇𝑎 reconstructions from the channel phantom for experimental 
𝜇𝑎 increases of 25%, 50% and 100% from baseline. The X-Z plane through the center of 
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the channel is shown. The % of target ∆𝜇𝑎 is indicated by the colorbar and by labeled 
isolines. Optical property changes up to 4.0 cm in depth can be detected when a threshold 
of 10% of target ∆𝜇𝑎 is utilized. It is of note that the accuracy of reconstruction degrades 
for larger ∆𝜇𝑎, which is expected for Rytov approximation (Bigio and Fantini 2016). 
These results indicate the wearable probe is capable of detecting subsurface 𝜇𝑎 
perturbations that are of the same magnitude as those anticipated during a breath hold 
challenge.  
 
Figure 4. 9 ∆𝝁𝒂 reconstructions using the Rytov approximation. Changes in 𝝁𝒂 are 
shown in the X-Z plane through the center of the channel. The color bar and isolines 
indicate the % of target ∆𝝁𝒂 reconstructed. The same regularization parameter, 
𝜶 = 𝟏, was used for all three reconstructions.  
4.3.5 Fall time analysis 
Figure 4.10 shows the relationship between probe acquisition speed and fall time 
coefficient extraction accuracy and precision for healthy breast (black), benign breast 
lesions (blue), and malignant breast (red) tissue types. Downsampling had a negligible 
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effect on overall accuracy. However, reduced acquisition speed degraded the precision of 
fall time extractions. Extraction uncertainties were as large as 27% at 0.1 Hz. 
 
Figure 4. 10 HHb fall time extraction accuracy and precision with respect to probe 
acquisition speeds. 
Figure 4.11 shows the effect of reducing the probe acquisition speed on the 
theoretical ability to separate benign tissue from malignant tissue. An area under the 
curve (AUC) of more than 0.9 was maintained until the acquisition speed was reduced to 
less than 0.2 Hz. The accuracy, precision, and ROC analysis strongly suggest that an 
acquisition rate of 0.2 Hz is sufficient for capturing fall time hemodynamics.  
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Figure 4. 11 ROC curve analysis for differentiating benign and malignant tissue 
types based on fall times in a simulated system as acquisition speeds are reduced 
from 1 Hz to 0.1 Hz.  
4.3.6 Normal volunteer results 
Figure 4.12 (a) shows the moving average of HHb changes for a female normal 
volunteer as she took a 30 second breath hold. After 60 seconds of baseline 
measurements, the subject stopped gas exchange, which accordingly led to higher HHb 
concentrations due to tissue oxygen consumption and vessel dilation. The maximum 
change of HHb for this subject reached 7.4 % when assuming a baseline HHb 
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concentration of 6.9 𝜇𝑀, which has been previously reported for pre-menopause breast 
tissue (Shah et al. 2004) Our result indicates a reasonable match with previous published 
results shown in Figure 4.12 (b) (Flexman et al. 2013), in terms of the initial 
enhancement during breath hold period, the normalized maximum changes in 
deoxyhemoglobin concentration from baseline, and the washout rate in the first 15 
seconds of breath release period. 
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Figure 4. 12 HHb concentration changes in healthy breast tissue during breath hold 
challenge. (a) Results from the wearable optical probe at Biomedical Optical 
Technologies Lab at Boston University, (b) results adapted from Flexman’s study at 
Columbia University 
4.4 Discussion 
This work introduced a high optode density, deep-tissue, and wearable imaging 
system designed for monitoring breast cancer patients during presurgical chemotherapy. 
Characterizations and validations of this prototype were performed with numerical 
simulations, solid and liquid tissue-simulating phantom measurements, and a healthy 
human subject measurement. 
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The system was characterized with a bevy of in vitro and in vivo tests. For 
example, measurements on a breast-mimicking silicone phantom revealed high precision 
(1.01%) and high signal quality. Additionally, the ability of the wearable probe to extract 
changes in absorption in an embedded inclusion was tested with a channel phantom. The 
results indicate highly accurate optical property reconstruction absorption perturbation as 
large as 50% of baseline. It should be noted, however, that the in vitro validation 
experiments in this work may have oversimplified the heterogeneity of tumor-bearing 
breast tissue. The inclusion used for our studies was regular and homogeneous, whereas 
tumors may have a hypoxic core with an irregular and proliferating periphery. 
Discrepancies between the assumed and the actual tissue geometry may affect 
reconstruction accuracy.  
In vivo validation of the wearable imaging system was implemented through 
breath hold measurement with a healthy female subject. Previous studies have suggested 
that breath hold induced tissue hemodynamics may be indicative of LABC patients’ 
response to NAC. Although the physiology of breath hold is far from being 
comprehensively understood, the fundamentals of gas exchange physiology between 
alveoli and capillaries have been well studied (Parkes 2006), as the diffusion of oxygen 
and carbon dioxide molecules is driven by the gradient of partial pressure between alveoli 
and the capillaries. Breath hold prevents gas renewal at alveoli, so that the partial 
pressure difference between alveoli and capillaries is gradually reduced. This brings 
down the exchange efficiency for both gases, which should have caused reduced tissue 
oxygen saturation. However, increased amount of carbon dioxide strongly dilates the 
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vessels, which accordingly increases tissue blood volume. Therefore, within breath hold 
period, these two effects will promote the concentration of deoxyhemoglobin and 
competing each other on the concentration of oxyhemoglobin. Measured tissue 
hemodynamic results confirmed this theoretical background, and the same observations 
were seen in previously published findings (Flexman et al. 2013; Gunther et al. 2018).   
The wearable probe had several limitations. For example, the acquisition speed 
could be increased to achieve finer temporal resolution of 3D tissue hemodynamics. The 
system is currently limited due to sequential scanning of measurement channels, and the 
settling time between successive optodes. An additional limitation is the current inability 
to dynamically change the LED forward current during measurements. This limits the use 
of optodes with the shortest and longest source detector separation due to saturation and 
low signal respectively. 
In the future, a normal volunteer study with larger sample size is planned to better 
validate the performance of this wearable system in monitoring breath hold 
hemodynamics. Promising results from normal volunteer study will lead to breast cancer 
monitoring to LABC patients in the clinical setting.  
To the best of our knowledge, this CW imaging system is the first demonstration 
of a wearable device on female breast tissue for rapid hemodynamic monitoring during 
breath hold challenge. It targets the first hours of neoadjuvant chemotherapy and holds 
potential to feedback real time treatment response. 
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CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS 
5.1 Summary 
The major contribution of this work lies in design and fabrication of a clinic-ready 
wearable physiological sensing device for breast cancer monitoring. This device not only 
has the potential to explore an uncharted domain in clinical monitoring devices (i.e. 
continuous measurements during treatment), but also provides a more patient-friendly 
and economical imaging method for tumor hemodynamics monitoring.  
In terms of hardware development, this work began with optical transducer 
selection, and evaluated the feasibility of electronics design using rigid PCBs. The 
electronics design was then improved and electric and optical components were migrated 
to a flexible PCB. The probe was accompanied by a silicone housing and was designed to 
adapt to the curvature of human breast. Based on the design experience from first two 
iterations of probes, a final generation probe was fabricated that featured a much higher 
density of optical transducers, and more versatile optical channel switching electronics. 
Additionally, the supporting electronics were miniaturized and  integrated into an 
electrical enclosure. 
Custom software was also developed to operate the probe. The probe described in 
Chapter 3 was equipped with software that provided real-time feedback of tissue 
hemodynamics. The probe described in chapter 4 included an interactive user-interface 
that provided instructions and feedback to normal volunteers measured during breath 
holds. 
In terms of system characterization, this work analyzed the signal quality, system 
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precision and accuracy in both in vivo and ex vivo experiments, and also demonstrated 
system performance in human volunteers. The wearable imaging system was successfully 
used to monitor fast tissue hemodynamics during cuff occlusion and breast holds. Results 
were in agreement with previous studies exploring these same hemodynamic challenges.   
In terms of physiological data processing, this work utilized 2-D and 3-D 
reconstruction methods of tissue optical and functional properties using analytical and 
numerical models. Tomographic simulations and measurements helped to guide the 
design of the optical transducer array during the system hardware development phase.  
Together, these results support the feasibility of breast tumor hemodynamic 
monitoring with this new wearable optical probe. 
5.2 Future directions 
Several future directions of this project are described below. The first relates to 
the clinical application, and the others relate to system hardware improvements. 
In the near future, it is anticipated that the clinical-ready prototype will be 
transferred to the clinical and used to perform wearable tissue imaging in LABC patients 
during the course of chemotherapy infusions. This will validate the ability to perform 
real-time monitoring of tumor hemodynamics, and potentially further confirm our 
previous finding that oxyhemoglobin flare occurs in pathologically responsive patients 
(Roblyer et al. 2011). 
The wearable device is limited by several system constraints that could be 
addressed in the future. The first related to the footprint of light sources and detectors. 
The current LEDs are in PLCC-2 packages; each one has a single LED chip. As shown in 
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figure 3.1, two separate LED packages are required for the current system. In the future, a 
single PLCC-4 package containing two LEDs could be used reduce the footprint of light 
source by 50%.  
The second hardware limitation is the electrical bandwidth of the CW imaging 
system. The system described in chapter 4 currently uses DC (non-modulated) light 
sources. Modulation is desired as it helps to eliminate pink noise. The rise time and fall 
time of the current photodiode sensing module are on the order of hundreds of 
microseconds, supporting modulation in the kHz range. It is possible that modulation in 
this range may limit or reduce the overall data acquisition rate as sample lengths need to 
be sufficient to capture the AC amplitude of the modulated signal. In the future, an 
optical detector with faster response may allow for modulated light detection without 
compromising acquisition speed.  
A third hardware limitation is related to the removal of motion artifacts. Future probe 
designs may take advantage of ICs that provide motion data of a subject under study. For 
example, Figure 5.1 shows a multi-chip module consisting of two dies integrated into a 
single QFN package. One die houses the 3-Axis gyroscope and the 3-Axis accelerometer. 
Motion artifacts identification and removal from optical sensing data could be allow 
higher accuracy with the wearable probe. 
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Figure 5. 1 MPU-9250 QFN application schematic for I2C operation 
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APPENDIX 
1. Gen2 – Wearable Electronics Design 
1.1 Schematic capture 
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1.2 PCB stack-up 
 
 
1.3 PCB layout (Top layer) 
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1.4 PCB layout (Bottom layer) 
 
1.5 Contributions 
This CAD design comes from joint collaboration from BOTLab and Fraunhofer 
CMI, USA. BOTLab contributed to the schematic capture, component selection, circuit 
test and troubleshooting. Fraunhofer transferred the schematic design from ExpressPCB 
to KiCad, and contributed to flexible circuit layout.  
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2. Gen3 – Wearable Electronics Design 
2.1 Schematic capture 
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2.2 PCB stack-up 
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2.3 PCB layout (Rigid top layer) 
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2.3 PCB layout (Flexible bottom layer) 
 
2.5 Contributions 
BOTLab and Fraunhofer CMI, USA. both contributed to the schematic capture, 
component selection, circuit test and troubleshooting.  
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3. Portable Electronic Enclosure Design 
3.1 Overview 
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3.1 Front view with dimensions (inch) 
 
 
3.2 Bottom view with dimensions (inch) 
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3.3 Back view with dimensions (inch) 
 
 
3.4 Side view with dimensions (inch) 
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3.5 Contributions 
This mechanical design is finished by BOTLab, and manufactured by Protocase (Sydney, 
Nova Scotia, Canada).  
 
4. Blood Liquid Phantom Recipe 
Total Volume:  
1200ml (in a cylindrical baking can) 
Content: 
Bovine Blood:  17ml (~25uM Hemoglobin)  
 Citrated, Pooled, 100 mL, Carolina Biological Supply Co.  
Intralipid:  48ml (~0.8/mm Mus’)  
 20% Intravenous Fat Emulsion, Fresenius Kabi 
PBS solution:  120ml  
 Phosphate-Buffered Saline (10X) pH 7.4, ThermoFisher  
DI water:  1015ml 
HCl (pH = 1):  Optional  
NaOH (pH = 13):  Optional 
Procedure: 
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1: Collect and pour DI water into baking can. 
2: Collect and pour PBS solution into a cylindrical baking pan. Stir the solution 
with a glass stirring rod. 
3: Collect and pour intralipid into baking pan, Stir the solution again. 
4: Collect bovine blood with pipette, and transfer blood to baking pan. Stir the 
solution again. 
5: Measure and adjust the pH of solution. (in most cases, the pH value is between 
7.4±0.5, which waives PH adjustment) 
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